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Abstract 
Hypertension (HTN) is a major risk factor for the development of 
cardiovascular disease, and it’s estimated that over 80 million adults in the 
United States have HTN.  Essential HTN often demonstrates sensitivity to salt, 
and reductions in dietary salt attenuate high blood pressure in this population. 
Evidence indicates that the paraventricular nucleus (PVN) of the 
hypothalamus is a key driver of HTN due to excess salt intake.  The cellular 
mechanisms whereby PVN neuronal activity is augmented in response to salt 
are largely unknown.  Previous work from our lab has demonstrated that small 
conductance calcium activated potassium (SK) channel function is diminished 
in the PVN in HTN induced by a 2% high salt (HS) combined with chronic 
infusion of angiotensin II (AngII) (AngII-salt HTN).  In study 1 we demonstrate 
SK channel dysfunction in AngII-salt HTN.  Furthermore, SK channel 
dysfunction was present in rats fed a HS diet alone indicating that dietary salt 
likely plays a dominant role in reducing SK channel function.  In study 2 we 
examined the contribution of the endoplasmic reticulum (ER), and intracellular 
organ largely responsible for intracellular Ca2+ homeostasis, in regulating 
sympathoexcitatory response in vivo, and neuronal excitability in vitro.  We 
demonstrate that inhibiting ER function in the PVN augments sympathetic 
nerve activity and blood pressure in vivo, and neuronal excitability in vitro.  We 
further demonstrate that HS diet augments excitability of PVN neurons through 
altered ER Ca2+ store function.  Collectively, we demonstrate that HS diet 
diminishes SK channel function in the PVN and altered ER Ca2+ regulation 
may contribute to the augmented neuronal excitability in the PVN due to HS 
intake.  Together, these mechanisms providing new and exciting targets for 
the treatment of salt-sensitive HTN.
1 
Chapter 1. Literature Review 
1.1 Introduction 
Cardiovascular disease (CVD) is the leading cause of death in the U.S., 
and approximately 86 million Americans are living with some form of CVD.1 
Hypertension (HTN) is a major risk factor for the development of CVD including 
coronary heart disease, stroke, congestive heart failure and fatal arrhythmias. 
It is estimated that over 80 million Americans either have HTN, or are taking 
anti-hypertensive medications.1  The development of new treatment strategies 
for HTN has the potential to significantly reduce the number of deaths each year 
due to CVD. 
1.1.1 Blood Pressure 
Blood is contained within the vasculature, and the hydrostatic pressure it 
exerts upon the walls of the blood vessels is known as blood pressure.2 
Contraction of the ventricles within the heart provides continuous circulation of 
blood from areas of high pressure to areas of low pressure within the body.  In 
healthy individuals, the highest arterial blood pressure (ABP) is generated 
during the systolic phase of the cardiac cycle (ventricular contraction), and the 
lowest ABP occurs during the diastolic phase (ventricular relaxation) of the 
cardiac cycle.  ABP in a healthy young individual is typically less than 120mmHg 
for systolic arterial pressure, and less than 80mmHg for diastolic arterial 
pressure.   HTN is defined as having a systolic arterial blood pressure of ≥ 
140mmHg and/or a diastolic arterial blood pressure of ≥ 90mmHg.3  
1.1.2 Blood Pressure Regulation 
Blood pressure levels are influence by a variety of systems including 
neural, hormonal and local control mechanisms.  Short-term control of ABP 
(minutes to hours) is regulated largely by the sympathetic nervous system 
(SNS) through the baroreflex.4  Stretch receptors in the aortic arch and carotid 
sinus sense ABP and send afferent signals to the nucleus tractus solatarii (NTS) 
in the brainstem.5  The baroreflex circuitry extends from the NTS to the caudal 
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ventrolateral medulla that further has axon projections to the rostral ventrolateral 
medulla (RVLM).6  The RVLM is a key excitatory site for sympathetic nerve 
activity (SNA),7, 8 and RVLM neurons have axon projections to the pre-
ganglionic sympathetic neurons in the spinal intermediolateral (IML) cell 
column.9  When baroreceptors sense that blood pressure is elevated, the RVLM 
is inhibited, resulting in a decrease in SNA, whereas a decrease in ABP will 
result in less inhibition of the RVLM, and an increase in SNA to restore ABP 
back to normal levels. SNA targeting the heart can augment heart rate and 
stroke volume to increase cardiac output (CO).  SNA targeting the vasculature 
also increases ABP by reducing blood vessel diameter; therefore, increasing 
total peripheral resistance (TPR).  Finally, SNA targeting the kidneys promotes 
fluid and Na+ retention through increased release of renin and production of 
angiotensin II (AngII).10   
Long-term control of ABP is heavily influence by the pressure-natriuresis 
mechanism within the kidneys.11, 12  Pressure-natriuresis alters ABP through 
alterations in renal excretion of water and salt.  When ABP increases, excretion 
of sodium (natriuresis) and water (diuresis) diminish total blood volume thereby 
reducing CO and returning ABP to a normal level.  Conversely, a decrease in 
ABP will cause retention of sodium and water to increase blood volume and 
cardiac output in order to return ABP to normal levels.  
1.1.3 Sodium Homeostasis 
Salt in the form of Sodium Chloride (NaCl) is an essential component of 
life and the body has multiple homeostatic pathways to ensure proper sodium 
balance.  Salt levels are high in the extracellular fluids whereas the intracellular 
fluids have a relatively low level of sodium.  Sodium depletion results in complex 
physiological and behavioral adjustments that work in concert to both conserve 
sodium and increase salt intake.13 The body is composed largely of water that 
is distributed into two main compartments, the extracellular fluid (ECF) and the 
intracellular fluid (ICF).14  Na+ levels are high in the ECF and low in the ICF 
whereas potassium (K+) levels are high in the ICF and low in the ECF. 
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Figure 1.1 Diagram of changes in body fluid distribution during negative and 
positive water balance.  Adapted from Anderson.14 
 
Cell membranes are highly permeable to water, but relatively impermeable to 
Na+.  The relationship between these two properties forms the basis for water 
balance between the ECF and ICF being dependent on sodium levels in the 
ECF, as approximately two thirds of total water in the mammalian body resides 
within the cells.   
Normal water balance and the relative distribution of water between the 
ICF and ECF is illustrated in Fig. 1.1A.  A state in which body water is lost is 
known as absolute dehydration.  As illustrated in Fig. 1.1B, the water volume of 
both the ICF and ECF is diminished triggering thirst behavior and release of 
anti-diuretic hormone (ADH) from the pituitary gland.  ADH stimulates 
reabsorption of water in the kidneys to conserve total body water volume.  
Conversely, an excess of total body water results in expanded volume of the 
ICF and ECF and dilution of solutes as depicted in Fig. 1.1C.  In this state, there 
is no thirst mechanism and ADH release is inhibited to diminish reabsorption of 
water in the kidneys.  Excess consumption of sodium results in a state termed 
relative dehydration.  In this state, increasing levels of Na+ in the ECF draws 
4 
water from the ICF into the ECF as shown in Fig. 1.1D.  In order to compensate 
for relative dehydration, the thirst response is activated, and ADH is released to 
conserve water in order to dilute the ECF.  Additionally, Na+ excretion by the 
kidneys is increased.  Fig. 1.1E illustrates a state of Na+ depletion, known as 
cellular hydration, where diminished Na+ concentration in the ECF results in 
expansion of the ICF and diminished total blood volume.  Several strategies are 
employed to conserve Na+ in this state. Augmented levels of AngII act directly 
on the vasculature to produce vasoconstriction as well as stimulate release of 
aldosterone from the adrenal gland.  Aldosterone acts directly on the kidneys to 
facilitate reabsorption of Na+ and preserve the prevailing level of sodium.   
1.2 Salt-Sensitive Hypertension 
HTN is a multi-system disorder with multiple contributing mechanisms. 
Figure 1.2 demonstrates the three prominent mechanisms that contribute to 
HTN including renal mechanisms, vascular mechanisms, and central neural 
mechanisms.  Mean arterial blood pressure (MAP) is directly proportional to CO 
and TPR and alterations in these three systems increase CO, TPR, or both, 
contributing to chronic increases in MAP. 
1.2.1 Renal Mechanism 
Strong evidence suggests that the kidneys play a significant role in HTN 
through the pressure natriuresis mechanism.  Tigerstedt and Bergman were the 
first to demonstrate that the kidneys influence ABP15, 16  They injected 
supernatant from homogenized rabbit kidneys into other rabbits and observed 
a significant increase in ABP.  They termed the substance “renin” and further 
demonstrated its presence in renal venous but not arterial blood.  Renin is 
liberated in the kidney and enters the blood where it converts Angiotensinogen 
to Angiotensin I.  Angiotensin I is converted to AngII by angiotensin converting 
enzyme (ACE).  Evidence indicates that chronic infusion of AngII increases 
intake of water and sodium,17, 18 and this response is augmented by addition of 
aldosterone.19, 20
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Figure 1.2 Mechanisms contributing to salt-sensitive hypertension.  A: Altered 
renal function in HTN results in diminished H2O and Na+ excretion contributing 
to increased CO.  B: The peripheral vascular mechanism contributes to HTN 
through vasoconstriction and increased TPR.  C: The central neural mechanism 
contributes to elevated CO through enhanced renal SNA, and increased TPR 
through vasoconstriction in other vascular beds. 
 
Pressure natriuresis is maintained through a relationship governed by 
ABP and renal Na+ and fluid excretion, termed the renal function curve.  Studies 
have demonstrated that the renal function curve is very steep in normotensive 
animals whereby small increases in ABP from the normal “set point” result in 
significant urinary Na+ and fluid excretion.  Conversely, a decrease in ABP will 
result in a significant drop in urinary Na+ excretion in order to maintain proper 
fluid volume and ABP.12, 21  In many forms of human and experimental HTN, the 
renal function curve is shifted to a higher ABP while Na+ excretion remains at 
normal levels allowing for chronic elevations of ABP that are not lowered 
through Na+ and fluid excretion.22, 23  Elevations in AngII have been shown to 
flatten the renal function curve resulting in less Na+ excretion at higher ABP, 
contributing to HTN.21  AngII, in combination with aldosterone, decreases 
excretion of fluid and Na+ in the kidneys resulting in an expansion of blood 
volume; therefore, increasing cardiac output and augmenting MAP (Fig 1.2).24-
27  The strongest evidence for the kidney being a major contributor to 
hypertension comes from studies involving kidney transplants.  Evidence 
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demonstrates that normotensive rats develop HTN when they received kidney 
transplants from hypertensive rats, thus leading to the hypothesis that HTN 
follows the kidney.28-30 
1.2.2 Vascular Mechanism 
 The vascular system is a key contributor to hypertension through 
changes in TPR.  Increases in TPR in salt-sensitive HTN occur through a variety 
of mechanisms that result in a narrowing of blood vessel diameter.  Numerous 
reports indicate that increases in vascular tone contribute to salt sensitive 
hypertension.  Endogenous ouabain (EO) is a substance secreted by the 
adrenal gland that has been reported to increase Ca2+ signaling and augment 
vascular myogenic tone through inhibition of Na+ pumps and enhanced 
contractility in vascular cells.31, 32  Reports indicate that EO levels are elevated 
by high salt diet,33 and correlate with ABP levels in human essential HTN,34, 35 
as well as animal models of HTN.36-38  
 Impairment of endothelial vascular relaxation is a prominent mechanism 
contributing to augmented TPR in essential and salt-sensitive HTN in 
humans,39-42 and animal models of salt-sensitive HTN.43-45  Nitric oxide (NO) is 
produced by endothelial cells and is a primary mediator of vascular relaxation.46  
Diminished NO signaling is a major factor in the augmented TPR observed in 
HTN.  Alterations in a number of pathways significantly diminish NO signaling 
in the vasculature with increased oxidative stress being the most prominent 
contributor to impaired endothelial vascular relaxation.40, 47, 48  Studies have 
consistently demonstrated that reducing oxidative stress in the vasculature 
reverses endothelial dysfunction, and increases vasculature relaxation in a 
variety of pathological conditions including HTN.49-52 
1.2.3 Central Neural Mechanism 
 The central nervous system is a key contributor to hypertension through 
targeted increases in SNA (Fig 1.2).  Increases of renal SNA (RSNA) stimulate 
secretion of renin from the kidneys resulting in AngII production and aldosterone 
secretion.  These mechanisms diminish excretion of H2O and Na+ to increase 
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CO. SNA targeting vascular beds results in vasoconstriction and increased 
TPR. 
Early evidence demonstrating over-activity of the SNS contributes to 
HTN involved examinations of plasma catecholamine levels in hypertensive 
human subjects. The majority of studies reported that plasma norepinephrine 
levels were consistently increased in young, hypertensive individuals.53   It 
should be noted that circulating norepinephrine represents a relative small 
amount of total norepinephrine within the body, and cannot account for regional 
differences in release and uptake. Studies examining direct multifiber 
recordings of muscle sympathetic nerve activity (MSNA) have reported that 
burst frequency of MSNA is augmented in pre-hypertensive54-56 and 
hypertensive subjects.55, 57-61 Measurement of MSNA is limited in that it cannot 
provide information on sympathetic traffic to internal organs such as the heart 
and kidneys.  Studies utilizing measurement of total norepinephrine spillover 
indicate that neuronal re-uptake of norepinephrine is impaired in subjects with 
essential HTN.62, 63  Studies further indicate that norepinephrine spillover from 
the heart and kidneys is augmented in hypertensive subjects.64, 65 Evidence 
indicates that the SNS plays a role in the pathogenesis of HTN, with the 
strongest evidence in young pre-hypertensive and hypertensive individuals. 
 Strong evidence for a contribution of the SNS to salt-sensitive HTN in 
animal models comes from studies demonstrating that chemical 
sympathectomy or ganglionic blockade prevent HTN in Dahl salt-sensitive 
rats.66, 67  Evidence suggests that alterations in compensatory mechanisms 
likely contributes to augmented SNS activity in response to HS intake.  Studies 
suggests that sympathetic activity is inhibited in Dahl salt-resistant rats in 
response to HS diet, but this response is not demonstrated in Dahl salt-sensitive 
rats.68  Furthermore, human studies employing salt loading indicate that salt-
resistant subjects have attenuated sympathetic activity in response to salt 
intake.69, 70  It has been further demonstrated that salt loading results in a reflex 
decrease in renin and AngII levels.13, 21  Additional evidence indicates that a HS 
diet in normal dogs resulted in an increased in cardiac output, but a decrease 
8 
in total peripheral resistance in order to maintain normal ABP.71  When AngII 
levels were clamped, the vasodilatory response was lost and the dogs became 
hypertensive in response to high salt diet.  These results indicate that a loss of 
reflex attenuation of the renin-angiotensin system in response to salt intake is a 
key contributor to high salt diet induced HTN.72 
1.2.4 Angiotensin II-High Salt Model 
The angiotensin II-high salt model (AngII-salt) is a physiological model of 
salt-sensitive hypertension.  HTN is induced through the interaction of 
circulating AngII and dietary salt, which together increase activity of the SNS 
resulting in “neurogenic” hypertension.  Sprague Dawley rats are fed a 2% HS 
diet for 4 weeks.  After the second week of HS diet an osmotic minipump is 
implanted subcutaneously to deliver AngII at a rate of 150 ng/kg/min. Figure 1.3 
demonstrates heart rate (HR) and MAP responses to AngII and vehicle infusion 
in rats fed a 0.4% normal salt (NS) diet, and rats fed a 2% high salt (HS) diet. 
HR was significantly attenuated in HS rats during days 3-6 of AngII infusion, but 
did not otherwise differ from NS rats.  AngII infusion alone significantly increased 
MAP for the entire 14 day infusion period in NS rats, but the response was 
significantly augmented by HS diet.73   
Evidence demonstrates that plasma norepinephrine and whole-body 
norepinephrine spillover are substantially augmented in HS compared to NS 
rats following 7 and 14-day infusions of AngII (Fig 1.4).74 In addition, ICV 
administration of the sodium channel/transporter blocker benzamil significantly 
attenuated MAP in AngII-salt HTN compared to vehicle control.75  AngII infusion 
alone is sufficient to generate HTN, but the combination of AngII and HS diet 
produces neurogenic hypertension driven primarily by the SNS. 
9 
Figure 1.3 Mean arterial blood pressure is augmented in AngII-salt HTN.  Heart 
rate (A) and MAP (B) response to chronic subcutaneous infusion of AngII (150 
ng/kg per minute) or saline vehicle in rats fed either a 2% or 0.4% NaCl diet. C, 
control day; A, AngII or vehicle infusion day. *Significant difference (P<0.01) 
between specific AngII infusion day and control. #Significant difference (P<0.01) 
between specific AngII infusion day of rats fed 2% NaCl vs rats fed 0.4% NaCl.73 
(Reprinted with permission from Hypertension. 2006; 48:927-33. Copyright 
2006, Wolters Kluwer Health, Inc.) 
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Figure 1.4 Norepinephrine Spillover is augmented in AngII-salt HTN.  Plasma 
norepinephrine (A), whole body norepinephrine clearance (B), and whole body 
norepinephrine spillover (C) during control and on AngII infusion days 7 and 14 
in rats fed 0.4% or 2% NaCl. *P<0.05 vs. control period. #Interaction P<0.05 
two-way ANOVA.74  (Reprinted with permission from Am J Physiol Regul Integr 
Comp Physiol. 2008; 294:R1262-7. Copyright 2008, The American 
Physiological Society). 
 
 
Previous studies have established that the splanchnic vasculature is a 
key target for the elevated SNA in this model of HTN.  One early study 
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demonstrated that MAP and mean circulatory filling pressure (MCFP), an index 
of venous smooth muscle tone, was significantly increased in AngII-salt rats 
compared to control.  Additionally, they further demonstrated that the response 
was abolished by ganglionic blockade with hexamethonium demonstrating the 
contribution of the SNS in generating AngII-salt HTN.73  Further studies revealed 
that celiac ganglionectomy (CGx) attenuated MAP and MCFP in AngII-salt HTN 
whereas renal denervation had no protective effect.76  Interestingly, chronic 
sympathetic nerve recording in AngII-salt HTN revealed no change in lumbar 
sympathetic nerve activity (LSNA) and an initial decrease in RSNA that returned 
to baseline levels 10 days after the start of AngII infusion, despite a significant 
increase of MAP.77 Collectively, these studies indicate that augmented 
splanchnic sympathetic nerve activity (SSNA) is likely an important contributor 
to the augmented MAP in this model of hypertension.  Only one study has 
previously measured SSNA in response to AngII infusion.  This study infused 
AngII and reported that SSNA was augmented on day 14 of the infusion.78  It is 
important to note that level of dietary salt was not reported in this study.  Chronic 
recording of SSNA in AngII-salt HTN remain to be reported, but indirect 
evidence indicates the importance of augmented SSNA in this model of HTN.  
The splanchnic vasculature is an important contributor to total peripheral 
resistance.  It is hypothesized that elevations in SSNA shifts blood from the 
venous system to arteries.  Veins are substantially more compliant than arteries 
and the shift of blood volume is an important mechanism to augment total 
peripheral resistance and ABP in this model.72 
 To date, the majority of studies exploring mechanisms in AngII-salt HTN 
have examined disease progression in the chronic model and noted the 
contribution of the SNS in the development of HTN.  Recently, studies have 
been performed to examine alterations in neuronal activity/properties in AngII-
salt hypertension to further elucidate mechanisms that contribute to the 
augmented SNA.  Bardgett et al. sought to determine the contribution of 
neuronal activity in the PVN in the maintenance of ABP in AngII-salt HTN.  They 
reported that bilateral microinjection of the gamma aminobutyric acid type A 
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(GABAA) receptor agonist muscimol elicited significantly greater decreases in 
SSNA, RSNA and MAP in AngII-salt rats compared to normotensive controls.79  
These results indicate that neuronal activity in the PVN is indeed required to 
maintain high SNA and ABP in this model of hypertension.  The cellular 
mechanisms responsible for sympathoexcitation in AngII-salt hypertension 
remain to be fully elucidated. 
 
1.3 Central Autonomic Regulation 
1.3.1 Circumventricular Organs 
Early studies demonstrated that infusion of solutes that are relatively 
impermeable to the cell membrane including NaCl and sucrose stimulate 
drinking and antidiuresis.80-83 Further studies demonstrated that central 
osmoreceptors located outside of the blood brain barrier (BBB) are responsible 
for stimulating thirst and release of arginine vasopressin (AVP) in response to 
cell membrane impermeable hyperosmotic stimuli.84 Additionally, the central 
sites governing osmotic regulation were suggested to lie in the anteroventral 
third ventricle and electrolytic lesions of the surrounding periventricular tissue 
significantly attenuated the drinking response to stimulation with hypertonic 
saline and AngII.85-88 Specialized structures labeled the circumventricular 
organs (CVO) lack a complete BBB and have access to circulating blood 
allowing the ability to sense osmolality and circulating AngII levels (Fig 1.3).  The 
subfornical organ (SFO) is a CVO that protrudes into the third ventricle of the 
brain.  The SFO is dense in angII type 1 receptors (AT1R)89 and microinjection 
of AngII into the SFO augments ABP.90  SFO neurons have excitatory axon 
projections either directly to the paraventricular nucleus, or indirectly through 
the median preoptic nucleus (MnPO).91, 92  The organum vasculosum lamina 
terminalis (OVLT) is a CVO located on the ventral-anterior wall of the third 
ventricle.93  OVLT neurons have the ability to sense plasma osmolality and 
sodium levels.94-96  Similar to the SFO, OVLT neurons have direct and indirect 
excitatory axon projections to the paraventricular nucleus97 that play a critical 
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role in augmenting sympathetic nerve activity in response to hyperosmolality.98, 
99  Collectively, the CVOs sense circulating AngII and plasma osmolality and 
transmit excitatory neural activity to the PVN (Fig 1.5).  
 
 
Figure 1.5 Central neural circuitry contributing to sympathetic activation in 
AngII-salt HTN.   
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1.3.2 Paraventricular Nucleus 
The hypothalamic PVN is situated between the central sensory and 
effector centers for the SNS (Fig 1.5).  The PVN consists of two distinct cell 
types including vasopressinergic or oxytocinergic magnocellular neurons,100-102 
and parvocellular pre-sympathetic neurons that project to the prominent 
excitatory centers for the SNS including the RVLM and spinal IML cell column 
(Fig 1.3).103-105 The PVN is strongly inhibited by the inhibitory neurotransmitter 
gamma-aminobutyric acid (GABA) in normotensive rats demonstrated in 
conscious,106, 107 and anesthetized conditions.108-110  Additionally, small 
conductance Ca2+ activated K+ channels likely play a role in limiting PVN 
neuronal excitability in normotensive rats.111 Interestingly, inhibition of the PVN 
is lost in multiple diseases involving fluid retention and the PVN becomes a 
driver of the augmented SNA in these disease states.  Studies have 
demonstrated both augmented excitatory and diminished inhibitory 
neurotransmitter signaling in the PVN in heart failure.110, 112-115 Additionally, 
studies have indicate that augmented neuronal activity in the PVN contributes 
to sympathoexcitation due to water deprivation.116-119   Finally, the PVN plays 
an important role in the pathogenesis of salt-sensitive hypertension.  Multiple 
reports indicate that lesions of the PVN attenuate ABP in Dahl salt-sensitive 
rats,120 spontaneously hypertensive rats,121, 122 and renal wrap HTN.123 Recently 
is has been reported that inhibition of the PVN in AngII-salt HTN diminishes 
SNA and ABP demonstrating the contribution of PVN neuronal activity in 
maintaining the enhanced SNA and ABP in salt-sensitive HTN.79 
1.3.3 Mechanisms Contributing to Augmented PVN Activity 
Neuronal activity is governed by the confluence of intrinsic membrane 
properties with local synaptic activity.  Alterations in either of these two distinct 
mechanisms can directly influence the excitability and firing rate of a neuron.  
Ion channels on the membrane surface largely determine intrinsic membrane 
properties whereas overall synaptic activity is determined through the balance 
of excitatory and inhibitor neurotransmitters binding to receptors on the neuron.  
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Numerous studies have demonstrated that neuronal activity in the PVN 
contributes to the augmented SNA and ABP in neurogenic hypertension through 
both synaptic and intrinsic mechanisms. 
1.3.4 Synaptic Mechanisms 
There are complex interactions among excitatory and inhibitory 
neurotransmitters with the PVN.  Evidence indicates that blocking GABAA 
receptors in the PVN augments local glutamate levels.124 In addition, 
sympathoexcitatory responses to GABA blockade in the PVN are attenuated by 
glutamate and AT1R receptor blockade.108, 109, 124  The Dahl salt-sensitive rat is 
a well-characterized model of neurogenic HTN.  Dahl salt-sensitive rats develop 
HTN in response to a high salt diet that is mediated in part through activation of 
the SNS.120  Studies in Dahl salt-sensitive rats have demonstrated augmented 
activity of the excitatory neurotransmitters AngII and glutamate in the PVN.125-
127 Furthermore, loss of GABA inhibition also contributes to sympathoexcitation 
in Dahl salt-sensitive rats.128  Similarly, HTN in spontaneously hypertensive rats 
is partially due to sympathoexcitaion and numerous studies have demonstrated 
augmented glutamatergic and diminished GABAergic signaling with the PVN of 
spontaneously hypertensive rats.129-133  To date, only one study has examined 
altered neurotransmitter signaling in the PVN in AngII-salt hypertension and 
reported that loss of PVN GABA inhibition contributes to sympathoexcitation.79  
Interestingly, they also reported that the high PVN neuronal activity was not due 
to the actions of local tumor necrosis factor alpha or microglia activation.  
Augmented synaptic activity has been consistently demonstrated in HTN and 
likely plays a significant role in augmenting PVN neuronal activity. 
1.3.5 Intrinsic Mechanisms 
Less is known regarding alterations of intrinsic membrane properties that 
contribute to augmented PVN neuronal activity in salt-sensitive hypertension.  
Intrinsic mechanisms are particularly important due to their potential for 
increased post-synaptic excitability contributing to significantly augmented 
neurotransmitter release. The A-type K+ current has previously been 
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demonstrated to modulate action potential waveform and firing frequency of 
PVN neurons with axon projections to the RVLM (PVN-RVLM).134  One study 
has previously reported that diminished A-type K+ current contributes to action 
potential broadening and augmented Ca2+ entry into the cell that could play a 
role in augmented neurotransmitter release in renovascular hypertension.135 
SK channels serve as negative-feedback regulators of neuronal 
excitability.  SK channels open in response to a rise in intracellular Ca2+ during 
action potentials and generate the medium afterhyperpolarization potential 
(mAHP) immediately following decay of an action potential (Fig 1.6).136-141  
Evidence indicates that SK channels are key regulators of excitability in PVN-
RVLM neurons and SK channel blockade significantly augments neuronal 
excitability.142  Blockade of SK channels via PVN microinjection of the selective 
SK channel blocker apamin in normotensive rats dramatically augments SNA 
(~300%) and ABP (~30mmHg) demonstrating their powerful inhibitory control in 
the PVN.111   
 
 
Figure 1.6 Representative drawing of an action potential with after-
hyperpolarization potential (AHP).  SK channels mediate the medium AHP to 
limit neuronal excitability. 
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Several studies have demonstrated that SK channel dysfunction 
contributes to the augmented neuronal excitability in neurogenic hypertension. 
Pachauau et al. demonstrated that spontaneous firing frequency was 
augmented in IML projecting PVN neurons of spontaneously hypertensive rats 
(SHR) compared to Wistar-Kyoto (WKY) control rats.143  In addition, blockade 
of SK channels with apamin augmented excitability neurons from WKY but not 
SHR indicating SK channel dysfunction in PVN-IML neurons in SHR rats.  They 
further demonstrated that the amplitude of the apamin-sensitive mAHP was 
significantly greater in WKY compared to SHR.  To date, one study has probed 
for intrinsic mechanisms contribution to augmented excitability/activity of PVN 
neurons in AngII-salt hypertension.  Chen et al. examined the contribution of SK 
channel in limiting neuronal excitability of PVN-RVLM neurons in AngII-salt 
hypertension.144  They reported that SK channel current amplitude and density 
was decreased in AngII-salt hypertension.  Additionally, the intrinsic excitability 
of PVN-RVLM neurons as measured by firing frequency in response to a ramp 
current protocol significantly augmented (Fig 1.7). Subthreshold depolarizing 
input resistance was also augmented in AngII-salt hypertension compared to 
control.  Bath application of the SK channel blocker apamin significantly 
augmented neuronal excitability of neurons in the normotensive group, yet had 
no effect on neurons from AngII-salt indicating significant SK channel 
dysfunction (Fig 1.7).  Additionally spike-frequency adaptation (SFA) was 
diminished in AngII-salt neurons (Fig 1.7). In normotensive neurons, termination 
of current pulses revealed an AHP whereas neurons in the AngII-salt group 
demonstrated a revealed after depolarization potential (ADP).  Collectively, 
these results indicate that diminished SK current in PVN-RVLM neurons likely 
augments neuronal excitability in AngII-salt HTN and could play a large role in 
the sympathoexcitation in this model of hypertension. 
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Figure 1.7 Excitability of PVN-RVLM neurons is augmented in AngII-salt HTN.  
A: Tracings from NT rats to a 200pA depolarizing current injection.  B: Tracings 
from 2 different PVN-RVLM neurons from HT rats to depolarizing current 
injections.  C: Stimulus response curve from NT (left) and HT (right) rats in the 
absence and presence of apamin.  Note that excitability was greater in HT than 
NT rats under control conditions and apamin only increased discharge in the NT 
group.  D:  Slope of the stimulus-response curve was greater in HT compared 
to NT.  Apamin significantly increased the slope in the NT group but not the HT 
group.  Interspike intervals (ISIs) plotted for trains action potentials revealed that 
average ISI and spike-frequency adaptation (ISI prolongation) were greater 
(right) among neurons from the NT than HT rats. *P,0.01, **P<0.001 apamin vs. 
control groups from NT rats.  #P<0.05 vs. NT groups in the absence of 
apamin.144 (Reprinted with permission from J Neurophysiol. 2010; 104:2329-37. 
Copyright 2010, The American Physiological Society). 
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1.4 Endoplasmic Reticulum 
The endoplasmic reticulum (ER) is an intracellular organelle that plays a 
significant role in protein folding, and intracellular Ca2+ homeostasis.  The ER 
also plays a diverse role in cell regulation and helps provide a mechanism to 
deal with homeostatic perturbations in order to ensure viability of the cell.145 
Proteins ultimately destined for secretion or trans-membrane residence are 
folded and mature within the lumen of the ER.145, 146  Proper protein folding is 
essential for cell viability and is dependent on aspects of the ER environment; 
therefore, alterations in the ER environment can have a large impact on protein 
folding and cell viability 147.  
1.4.1 ER Stress 
Protein synthesis is a very delicate process that requires strict quality 
control to ensure aberrant proteins are not released for functional use 148. The 
ER requires specific properties in order to optimally process and release 
functional proteins including high levels of Ca2+ and adenosine triphosphate 
(ATP) compared to the cytosol, along with an oxidizing environment in order to 
ensure the formation of disulfide bonds.149  Changes in energy availability or 
perturbations in intracellular Ca2+, and/or an oxidative insult are just a few 
examples of how the ER of a cell can be altered to improperly synthesize or 
produce mis-folded proteins.  Mutations in transcription or translation of proteins 
can also result in mis-folded proteins.150  Studies indicate that close to 30% of 
new proteins are mis-folded and require corrections to the structure before 
being released from the ER.151 The accumulation of a large number of mis-
folded proteins within the ER triggers adaptive cellular strategies to return the 
cell to the homeostatic norm in a process called the unfolded protein response 
(UPR) triggering a pathological condition known as ER Stress.152  Recently, 
evidence has emerged that ER stress may play a role in the enhanced 
sympathetic outflow in hypertension, however, the mechanism(s) remain to be 
determined.153, 154 
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1.4.2 Intracellular and ER Ca2+ Regulation 
The ER is a key regulator of intracellular Ca2+ through the ER Ca2+ store.  
Ca2+ is an important second messenger that regulates many processes within a 
large variety of cell types.  Neuronal Ca2+ signaling plays an important role in 
regulating excitability, synaptic activity, and gene expression.155  Therefore, 
neuronal Ca2+ signaling is a highly regulated process involving voltage-gated 
membrane Ca2+ channels, metabotropic receptors including AT1, and Ca2+-
induced Ca2+ release (CICR) from Ca2+ stores in the ER. The ER Ca2+-ATPase 
actively pumps Ca2+ across the ER lumen resulting in Ca2+ levels that are 
significantly higher (~1mM) compared to the cytoplasm (100nM) (Fig 1.8).149  
Release of Ca2+ from the ER is mediated through two types of ligand gated Ca2+ 
channels including inositol-1,4,5-triphosphate receptors (IP3R), and ryanodine 
receptors (RyR).155, 156  IP3R activation occurs through rising levels of inositol-
1,4,5-triphosphate due to synaptic activation of metabotropic neurotransmitter 
receptors including, AT1 receptors, prominently located in the PVN (Fig. 1.8).157  
RyR activation occurs through rising levels of intracellular Ca2+ during action 
potentials (Fig 1.8).156  SK channels are activated by a swift rise in intracellular 
Ca2+ primarily mediated through voltage-gated Ca2+ channels and CICR from 
the ER stores.136 Studies report that inhibition of ER Ca2+ release diminishes 
the mAHP primarily mediated by SK channels in sympathetic neurons 
demonstrating the role of ER Ca2+ in SK channel activation.158, 159  Altered ER 
Ca2+ regulation could play an important role in SK channel dysfunction and 
augmented neuronal excitability in the PVN. 
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Figure 1.8 Representative diagram of intracellular Ca2+ regulation.  High ER 
Ca2+ levels ([Ca2+]er]) are maintained through the ER Ca2+ ATPase.  Ca2+ entry 
from voltage dependent Ca2+ channels (VDCC’s) stimulates Ca2+ release from 
ryanodine receptors (RYR) on the ER membrane.  Inositol triphosphate (IP3) 
from g-protein coupled receptors (GPCL) stimulates Ca2+ release from IP3 
receptors (IP3R) on the ER membrane.  Intracellular Ca2+ ([Ca2+]i) binds with 
calmodulin (CaM) and together the complex activates SK channels. Adapted 
from Paschen.149 
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1.5 Summary and Hypothesis 
Salt-sensitive hypertension is a complex disorder involving the 
interactions of multiple systems within the body.  Evidence indicates that 
disruption of compensatory mechanisms normally responsible for excretion of 
excess salt from the body play a substantial role in HTN due to HS diet.  
Numerous studies have demonstrated that the central nervous plays a dominant 
role in AngII-salt HTN through sustained activation of the SNS.  The 
hypothalamic PVN is an important regulator center due to its position between 
the sensory and effector centers for the SNS.  Evidence indicates that PVN 
neuronal activity is augmented in AngII-salt hypertension and is a driver of the 
high level of SNA and ABP.  To date little is known regarding cellular 
mechanisms in the PVN that contribute to the augmented neuronal 
excitability/activity in AngII-salt HTN.  Additionally, while numerous studies have 
examined synaptic mechanisms that contribute to augmented PVN neuronal 
activity in various models of neurogenic hypertension, less is known regarding 
intrinsic cellular mechanisms.  
 
Hypothesis 1:  Our laboratory has previously reported that SK channel 
dysfunction augments excitability of PVN-RVLM neurons in AngII-salt HTN.  
Additionally, we have demonstrated that SK channel blockade in the PVN 
significantly augments SNA and ABP in normotensive anesthetized rats.  
Therefore, in study 1, we hypothesized that SNA and ABP responses to 
PVN SK channel blockade would be attenuated in AngII-salt HTN due to 
SK channel dysfunction.  Furthermore, we sought to examine the individual 
contributions of HS and AngII to PVN SK channel dysfunction.  
 
Hypothesis 2:  The ER is a prominent regulator of intracellular Ca2+ and CICR 
from the ER during action potentials is a prominent activator of SK channels.  
To date, studies have not examined the contribution of the ER in regulating 
neuronal excitability in the PVN, or its contribution to SNA and ABP.  We 
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hypothesized that inhibition of ER Ca2+ function in the PVN would 
augment SNA and ABP.  In study 1, we demonstrate dysfunction of SK 
channels in rats fed a 2% HS diet; therefore, we further hypothesized that 
dysfunction of the ER Ca2+ store may be an underlying mechanism 
contributing to SK channel dysfunction and sympathoexcitation due to HS 
diet. 
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Chapter 2.  
 
Sympathoexcitation in ANG II-salt Hypertension involves 
Reduced SK Channel Function in the Hypothalamic 
Paraventricular Nucleus.1 
 
2.1 Introduction  
 Studies suggest that the central nervous system substantially contributes 
to AngII-salt hypertension (AngII-salt HTN) through elevations in sympathetic 
nervous system (SNS) activity.74, 76, 77, 79  Prominent forebrain circumventricular 
organs including the organum vasculosum lamina terminalis (OVLT) and 
subfornical organ (SFO) lack a complete blood brain barrier and therefore have 
the ability to detect alterations in plasma osmolality and AngII levels,99, 160-163 
and transmit efferent activity to the hypothalamic paraventricular nucleus 
(PVN).98, 164  PVN neurons, in turn, have axon projections to the spinal 
intermediolateral (IML) cell column and the rostral ventrolateral medulla 
(RVLM),104, 105 the main excitatory centers that play an important role in 
regulating sympathetic nerve activity (SNA).7 
 The PVN is a key regulator of SNA given its prominent position between 
the sensory and effector components of the SNS, and enhanced PVN activity 
has been demonstrated in a variety of cardiovascular diseases.72, 121, 165  
Evidence demonstrates that enhanced neuronal activity within the PVN is 
required for the maintenance of several models of neurogenic HTN including 
AngII-salt.79, 121, 166, 167  A number of studies have demonstrated an up-regulation 
                                                 
1 The material contained in this chapter was previously published in American Journal of 
Physiology- Heart & Circulatory Physiology.  Reprinted with permission from Larson RA, Gui L, 
Huber MJ, Chapp AD, Zhu J, LaGrange LP, Shan Z and Chen QH. American Journal of 
Physioliology- Heart and Circulatory Physiology. 2015; 308:H1547-55.  Copyright 2015, The 
American Physiological Society. 
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of excitatory glutamatergic and angiotensinergic signaling within the PVN in 
hypertensive rats.168-171  Furthermore, evidence demonstrates the role of GABA 
inhibition on PVN neurons,172, 173 and that GABA dis-inhibition contributes to the 
augmented SNA in HTN.174, 175  To date, little information is available regarding 
alterations of intrinsic membrane properties of PVN neurons in HTN.  One 
previous study by Sonner et al demonstrated a reduction in potassium A-current 
in PVN-RVLM neurons in renal-vascular HTN that contributed to augmented in 
vitro spontaneous neuronal discharge.176  
 Small conductance calcium activated potassium (SK) channels act as 
negative feedback regulators of neuronal excitability through their influence on 
the medium after-hyperpolarization potential (mAHP).136-141  Previous studies 
have demonstrated that SK channels greatly influence excitability in PVN 
neurons with axon projections to the rostral ventrolateral medulla (PVN-
RVLM),142 and reduced SK channel current significantly enhanced the 
excitability of PVN-RVLM neurons in rats with AngII-salt HTN.144  Very recently, 
Pachuau et al has reported that diminished SK current contributed to the 
increased excitability of spinal IML projecting PVN (PVN-IML) neurons in 
spontaneous hypertensive rats (SHR).143  Furthermore, our lab has recently 
reported that blockade of SK channels in the PVN in normotensive rats 
substantially augments SNA and ABP in vivo.111  The present study was 
performed to determine if SK channel dysfunction is present in the PVN of 
anesthetized rats with AngII-salt HTN.  In addition, recent evidence suggests 
that the neurogenic phase of AngII-salt HTN is more dependent on the level of 
dietary salt.75  Therefore, we examined the individual contributions of high salt 
(HS) diet and AngII alone to PVN SK channel dysfunction.  
 
2.2 Materials and Methods 
2.2.1 Animals 
 Male Sprague-Dawley rats (n=48, 200-300 g) purchased from Charles 
River Labs (Wilmington, MA, USA) were housed in a temperature controlled 
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room (22-23°C) with a 12:12 hour light-dark cycle.  Chow and tap water were 
available ad libitum unless otherwise noted. All experimental and surgical 
procedures were carried out under the guidelines of the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals with the approval of 
the Institutional Animal Care and Use Committee at Michigan Technological 
University.  
2.2.2 Protocols of Animal Experimental Model 
 Rats in the control group consumed a normal salt (NS, 0.4% NaCl) diet 
whereas rats in the high salt (HS) group were placed on a high salt (2% NaCl) 
diet for 4 weeks.  The AngII-salt hypertension group (AngII-salt HTN) was fed a 
HS diet for 4 weeks and received a systemic infusion of Ang II (150 ng/kg/min) 
subcutaneously during the last 2 weeks on the HS diet. The AngII administration 
only (AngII) group was fed a NS diet for 4 weeks and AngII was infused 
subcutaneously for the last 2 weeks.  For AngII-salt HTN and AngII groups, 
animals were anesthetized with isoflurane (3% in O2) and an osmotic mini pump 
(2ML2, Alzet) was implanted subcutaneously to deliver AngII (150 ng/kg/min) 
for two weeks prior to experimentation.  
2.2.3 Experiment Preparation 
 Rats were anesthetized with an intraperitoneal injection of a mixture 
containing α–chloralose (80 mg/kg) and urethane (800 mg/kg).  Adequate depth 
of anesthesia was determined by absence of corneal or pedal reflexes.  A water-
circulating pad maintained body temperature. A left femoral artery was 
catheterized for measurement of arterial blood pressure (ABP), and a left 
femoral vein was catheterized for administration of drugs.  Heart rate (HR) was 
obtained from the R-wave of the electrocardiogram (lead I). Following tracheal 
cannulation, rats were ventilated with oxygen rich room air.  End-tidal PCO2 
(Capstar-100, Cwe Inc) was continuously monitored to ensure it was within 
normal limits (35 to 40 mmHg).  Rats were paralyzed with continuous infusion 
of gallamine trethiodide.  Adequate depth of anesthesia following paralysis was 
determined by lack of pressor responses to noxious foot pinch.  Supplemental 
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doses of anesthesia equal to 10% of initial dose were given as needed.  All 
animals were allowed to stabilize for at least 2 hours following surgery to ensure 
stability of recorded variables.   
2.2.4 Recording of Sympathetic Nerve Activity 
 A left flank incision was utilized to view and isolate a left renal and a 
postganglionic splanchnic sympathetic nerve from the surrounding tissue.177 
Nerve bundles were mounted on separate stainless steel wire electrodes (A-M 
Systems 0.127-mm OD) and covered with silicon-based impression material 
(Coltene, Light Body).  The signal was directed to an AC amplifier (P511, Grass 
Technologies) equipped with half-amplitude filters (band pass, 100 to 1,000 Hz) 
and a 60-Hz notch filter.  The processed signal was rectified, integrated (10-ms 
time constant), and digitized at a frequency of 5,000 Hz using a 1401 Micro3 
analog-to-digital converter and Spike 2 software (Version 7.04, Cambridge 
Electronic Design, Cambridge, UK). 
2.2.5 PVN Microinjection 
 Animals were placed in a stereotaxic head frame with the skull level 
between bregma and lambda.  The dura was exposed by removing a small 
piece of the skull and a single-barreled glass microinjector pipette was lowered 
vertically into the PVN.  Stereotaxic coordinates used were as follows (in mm):  
1.2 to 1.6 caudal to bregma, 0.5 lateral to midline, and 7.0 to 7.2 ventral to dura.  
The SK channel blocker apamin (Sigma) was dissolved in saline and the pH 
was adjusted to 7.2.  The SK channel activator CyPPA (Tocris) was dissolved 
in DMSO.  Apamin (12.5 pmol) or CyPPA (5 nmol) were administered via 
bilateral PVN microinjection in a volume of 50 nl per side with a pneumatic pump 
(WPI).  The micropipette was withdrawn between bilateral microinjections and 
the approximate interval between bilateral injections was ~2 minutes.  Following 
each experiment, Chicago blue dye (2% in saline, 50 nl) was injected into the 
PVN to mark the injection sites and provide an estimate of drug diffusion area.  
Brains were removed and post-fixed in 4% paraformaldehyde and then 
transferred to 30% sucrose-PBS.  The hypothalamus, including the PVN area, 
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was sliced in coronal sections and microinjection sites were visualized under 
brightfield microscopy.  
2.2.6 Punched Brain Tissues from Rats 
 Separate groups of NS control and AngII-salt HTN rats were deeply 
anesthetized with 5% isoflurane and then decapitated. Brains were quickly 
removed and were put in the rat brain matrix pre-frozen with dry ice. The 
hypothalamic PVN were punched out with a 12-gauge needle (inner diameter 
1.5 mm). To identify hypothalamic PVN tissue, the optic tract was identified and 
a 1 mm thick brain section was taken from the rostral end point of the optic tract. 
Samples were frozen in liquid nitrogen and stored at -80oC for western blot 
analysis of SK channel protein. 
2.2.7 Western Blot Analysis of SK Channel Protein  
 Frozen brain tissues were homogenized in buffer (50 mM Tris-base, 1.0 
mM EDTA, 150 mM NaCl, SDS (0.1%), TritonX-100 (1%), sodium deoxycholate 
(1%), 1 mM PMSF, pH 7.4, Sigma) complete with protease inhibitors (Leupeptin 
0.1 mM and phenylmethylsulfony fluoride 0.3 mM, Sigma) and stirred for 30 min 
at 4°C. Centrifugation with 12000 rpm at 4°C was performed for 5 min. The 
supernatant was collected and the protein concentration was determined in 
triplicate by a Bio-Rad DC protein assay Kit at absorbance of 750 nm using 
Bovine Serum Albumin as a standard. Aliquots were stored at −80°C until 
analyzed, at which time the 75 μg protein of each sample was separated using 
sodium dodecyl sulfate-polyacrylamide gel (10%) electrophoresis (SDS-PAGE) 
followed by electrophoretic transfer of proteins from the gel to a nitrocellulose 
membrane (Bio-Rad). The membranes were blocked with 5% non-fat milk for 1 
hr at room temperature, washed three times, and probed with a primary rabbit 
KCa2.1, KCa2.2 and KCa2.3 antibodies (Alomone) (1:500) or mouse anti-β-
actin (Santa Cruz) overnight at 4°C. The membranes were incubated with goat 
anti-rabbit IgG-HRP secondary antibodies or goat anti-mouse IgG-HRP 
secondary antibodies (Santa Cruz) for 1 hr at room temperature, and then 
detected with enhanced chemiluminescence. 
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2.2.8 Data Analysis 
 Summary data are expressed as mean ± SE.  SSNA and RSNA were 
determined as an average of the rectified, integrated signal.  Baseline values of 
all variables were obtained by averaging a 10-min segment of data immediately 
preceding PVN microinjection in anesthetized rats.  SSNA, RSNA, MAP and HR 
responses to apamin or CyPPA were obtained by averaging a 2-min period 
centered on the maximal response.  Data are presented as percent (%) change 
from baseline after subtracting background noise determined with bolus 
injection of the ganglionic blocker hexamethonium (30 mg/kg).  Data were 
analyzed by one-way ANOVA.  Post-hoc analysis was performed with Newman-
Keuls Multiple Comparison Test. Differences were considered statistically 
significant at a critical value of p < 0.05. 
 
2.3 Results 
2.3.1 AngII-salt HTN 
 Baseline hemodynamic variables from anesthetized animals (n=34) are 
shown in Table 2.1.  ABP was significantly elevated in the AngII-salt HTN group 
compared to normotensive control rats on a NS diet.  Subcutaneous infusion of 
AngII alone elevated ABP, but the increase did not reach statistical significance, 
whereas HS alone had no effect on ABP.  HR was not significantly different 
among any of the groups.   
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Table 2.1 Baseline MAP and HR in anesthetized rats 
 
Values are mean ± standard error; n= number of rats; HR-heart rate; MAP-mean 
arterial pressure; NS-normal salt (0.4%); AngII-angiotensin II; HS-high salt (2%); 
HTN-hypertension; * P<0.05 vs NS Control. 
 
 
2.3.2 Effects of PVN-Injected SK Channel Blocker on SSNA, RSNA, MAP 
and HR  
Consistent with data we previously published,111 bilateral microinjection 
of the SK channel blocker apamin into the PVN markedly increased SSNA, 
RSNA, MAP and HR in control rats fed a NS diet.  Figure 2.1 demonstrates 
representative raw tracings from a rat with a NS diet (left) before and after 
bilateral microinjection of apamin (12.5 pmol, 50 nl) into the PVN.  This dose of 
apamin was previously shown to be the minimum dose to elicit a maximum ABP 
and SNA response in the PVN.111  Collectively (n=8) PVN apamin increased 
SSNA (+263.5 ± 39.7%), RSNA (+179.8 ± 19.3%), MAP (+36.7 ± 4.4 mmHg) 
and HR (+37.7 ± 12.3 beats/min) as shown in Figure 2.3 summary data. 
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Figure 2.1 Representative traces in response to PVN apamin. Heart rate (HR), 
splanchnic sympathetic nerve activity (SSNA), renal SNA (RSNA) and arterial 
blood pressure (ABP) responses to bilateral paraventricular nucleus (PVN) 
microinjection of apamin (12.5 pmol) in a rat with normal salt (NS) control (left) 
and a rat with AngII-salt hypertension (HTN, right).  A: bilateral PVN injection 
(50 nl each) of apamin (arrowheads) markedly increased HR, SSNA, RSNA and 
ABP in NS control whereas the responses were obviously attenuated in AngII-
salt HTN compared to NS control.  B: Left, 5s trace of SSNA (top) and RSNA 
(bottom) prior to injection of apamin into PVN.  Right 5s trace of SSNA (top) and 
RSNA (bottom) after injection of apamin into PVN. 
 
The main goal of this study was to determine in vivo whether SK channel 
function is altered in the PVN in rats with AngII-salt HTN.  The right column of 
Figure 2.1 shows a representative response to bilateral PVN microinjection of 
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apamin (12.5 pmol, 50 nl) in a rat with AngII-salt HTN.  In contrast to 
normotensive control rats with a NS diet, summary data (n=7) presented in 
Figure 2.3 demonstrates that maximum increases in SSNA, RSNA and MAP 
elicited by PVN apamin were significantly attenuated in AngII-salt HTN rats 
(+36.4 ± 15.7%, p < 0.05 versus NS for SSNA; +25.3 ± 16.2%, p < 0.05 versus 
NS for RSNA; +11.3 ± 6.2 mmHg, p < 0.05 versus NS for MAP).  While the 
increase in HR evoked by PVN apamin was blunted in rats with AngII-salt HTN 
compared to NS control group, it did not reach statistical significance (+4.8 ± 
8.1 beats/min, p > 0.05 versus NS). 
A secondary goal of the present study was to examine the relative 
contributions of a HS diet only or subcutaneous infusion of AngII (150 ng/kg/min) 
alone to PVN SK channel dysfunction.  Figure 2.2 shows a representative 
response to bilateral PVN microinjection of apamin (12.5 pmol, 50 nl) in a rat on 
a HS diet (left).  Summary data (n=7)  presented in Figure 2.3 demonstrates 
that maximum increases in SSNA, RSNA, and MAP elicited by PVN apamin 
were significantly attenuated in rats with a HS diet (+125.5 ± 21.5%, p < 0.05 
versus NS for SSNA; +62.9 ± 17.3%, p < 0.05 versus NS for RSNA; +19.9 ± 5.3 
mmHg, p < 0.05 versus NS for MAP).  Similarly, the increase in HR evoked by 
PVN apamin was blunted in rats with a HS diet, but did not reach statistical 
significance (+15.1 ± 10.9 beats/min, p > 0.05 versus NS).  While there is no 
statistically significant difference, the sympathoexcitatory and pressor 
responses elicited by PVN apamin in the HS group are less blunted compared 
to that in AngII-salt HTN animals.   
Representative raw tracings of bilateral PVN microinjection of apamin 
(12.5 pmol, 50 nl) in a rat with subcutaneous infusion of AngII alone are depicted 
in the right column of Figure 2.2.  Interestingly, although the RSNA responses 
to PVN apamin (+80.4 ± 35.2%, p < 0 .05 versus NS) in rats with subcutaneous 
infusion of AngII alone were significantly attenuated compared to control rats 
with a NS diet, SSNA (+208.7 ± 66.11%), MAP (+35.3 ± 2.1 mmHg) and HR 
(+16 ± 5.4 beats/min) responses to PVN apamin in rats with AngII treatment 
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alone (n=7) shown in Figure 2.3 were not statistically different (p > 0.05) from 
that in rats with a NS diet.  
 
Figure 2.2 Representative traces in response to PVN apamin in NS and AngII 
only. SSNA, RSNA and ABP responses to bilateral PVN microinjection of 
apamin (12.5 pmol) in a rat with a high salt (HS) diet alone (left) or systemic 
Angiotensin II (AngII) infusion alone (right).  A: bilateral PVN injection (50 nl 
each) of apamin (arrowheads) in a rat with a HS intake increased SSNA, RSNA 
and ABP in a similar manner to a rat with AngII-salt HTN (Figure 1, right).  
Bilateral injection (50 nl each) of apamin (arrowheads) in a rat with systemic 
AngII infusion increased ABP in a similar manner to a rat with NS control 
whereas SSNA and RSNA responses were obviously attenuated compared to 
the NS control (Figure 1, left). B: Left, 5s trace of SSNA (top) and RSNA 
(bottom) prior to injection of apamin into PVN.  Right 5s trace of SSNA (top) and 
RSNA (bottom) after injection of apamin into PVN. 
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Figure 2.3 Summary data showing the changes in SSNA, RSNA, MAP and HR 
in response to bilateral microinjection of apamin into the PVN in NS (normal 
salt) control, AngII-salt HTN (hypertension), HS (high salt) alone, and systemic 
AngII infusion alone groups.  *p<0.05 vs NS controls; † vs AngII-salt HTN (1-
way ANOVA; Newman Keuls Multiple Comparison Test). 
2.3.3 Effects of PVN-Injected SK Channel Activator on SSNA, RSNA, MAP 
and HR   
Initial experiments demonstrated loss of PVN SK channel function in 
AngII-salt HTN.  In an effort to further determine the role of SK channels in 
regulating sympathetic outflow in this disease model, we performed bilateral 
microinjections of the SK channel activator, CyPPA (5.0 nmol, 50nL/each) into 
the PVN.  This dose of CyPPA has been reported to effectively activate the SK 
channels in vivo.111  CyPPA microinjection (n=5) into the PVN did not 
significantly alter SSNA (+14.2 ± 4%), RSNA (+7.0 ± 8%), MAP (-5.2 ± 3.1 
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mmHg), and HR (0.2 ± 7.0 beats/min) compared to baseline (p > 0.05 vs. 
baseline). 
2.3.4 Histological Analysis  
 Histological examinations of coronal brain slices from similar rostral-
caudal positions were performed in order to estimate drug diffusion area within 
the hypothalamus.  Figure 2.4A demonstrates a composite dye diffusion area 
made by overlying slices from several different brains to show the outermost 
distribution of dye. Figure 2.4B shows a representative of a single injection 
tracing within the PVN.  Dye distribution was largely contained within the area 
encompassing the PVN.  Note that the composite dye diffusion area 
demonstrated in Figure 2.4A is larger than any single tracing from an individual 
brain but represents the widest possible distribution of injected dye for the entire 
group. 
2.3.5 Comparison of SK Channel Protein Expression 
 We compared the protein expression (western blot analysis) of SK1-3 
channels in the hypothalamic PVN between normotensive control rats with a NS 
diet (n=7) and AngII-salt HTN animals (n=7).  No statistically significant 
difference in PVN SK1-3 expression was detected between NS control and 
AngII-salt HTN animals (Figure 2.5A&B). 
 
   
 
 
 
36 
 
 
Figure 2.4 Schematic representation of coronal sections throughout the rat 
hypothalamus.  A: shaded areas indicate brain regions exposed to dye utilized 
to mark the injection sites bilaterally.  The shape of each area was determined 
by overlaying tracings of the outermost diffusion area of injected dye (50 nl) 
observed on each section through the paraventricular nucleus (PVN).  B: 
representative single bilateral injection of dye within the PVN (50nl of 2% 
Chicago blue dye, each).  AH, anterior hypothalamic area; 3V, third cerebral 
ventricle; RCh, retrochiasmatic area; MPO, medial preoptic nucleus; opt, optic 
tract; SOX, supraopticdecussation; StHy, striohypothalamic nucleus. 
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Figure 2.5 Expression of SK1-3 channels in hypothalamic PVN.  A: Western 
blot analysis showing protein expression of SK1-3 channels between rats with 
NS control group and AngII-salt HTN animals.  B: Summary data showing no 
significant statistical difference in protein expression of SK1-3 channels in the 
punched PVN between NS control group (n=7) and AngII-salt HTN animals 
(n=7). All values were normalized to β-actin. 
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2.4 Discussion 
 The PVN is a key site for the integration of SNA, and increased PVN 
neuronal activity is essential to maintain the elevated levels of ABP in AngII-salt 
HTN.79, 121  Here, we demonstrate a down-regulation of SK channel function in 
the PVN, which may underlie the central neuronal mechanisms of increased 
sympathetic outflow in rats with AngII-salt HTN.  We report three novel findings. 
First, SSNA, RSNA and MAP responses to SK channel blockade in the PVN 
were attenuated in AngII-salt HTN compared to normotensive rats with a NS 
diet indicating a loss of PVN SK channel function in animals with treatment of 
systemic infusion of angiotensin II in combination with a HS (2% NaCl) diet. 
Second, SSNA, RSNA and MAP responses to PVN SK channel blockade in rats 
with a HS diet alone were attenuated compared to control animals with a NS 
intake in a similar manner to the AngII-salt HTN group indicating that perhaps 
HS intake is a larger contributor to SK channel dysfunction in the PVN in animals 
with AngII-salt HTN.  Lastly, while SNA responses to PVN apamin trended 
towards an attenuated response, with only RSNA demonstrating a significant 
difference in rats with systemic AngII infusion only, MAP responses were similar 
to animals with a NS diet. This evidence indicates that HS intake, rather than 
the systemic infusion of AngII, may play an important role in down-regulating 
SK channel function in PVN contributing to the elevated sympathetic outflow in 
AngII-salt HTN.  
Previous studies have demonstrated chronic Ang II-salt treatment 
induces a neurogenic hypertension,74, 79, 178 however, little is known yet about 
the cellular mechanisms that contribute to the elevated sympathetic outflow in 
this hypertensive model.  The current study is the first to demonstrate 
impairment in SK channel function in the PVN of rats with AngII-salt HTN in vivo.  
In line with our previous work,111 SK channel blockade in the PVN in normal rats 
elicited a significant augmentation in SSNA and RSNA displaying the 
contribution of SK channel inhibition to PVN neuronal excitability and its 
influence on sympathoexcitation.  In the current study, SSNA, RSNA and ABP 
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responses to SK channel blockade in the PVN were substantially attenuated in 
rats with AngII-salt HTN compared to control animals with NS intake indicating 
a large degree of SK channel dysfunction.  SK channel function in AngII-salt 
HTN rats has previously been studied using an in vitro whole-cell patch clamp 
design under brain slice preparation to examine pre-sympathetic PVN 
neurons144.  Similar to the present study, it was demonstrated that blocking SK 
channels of pre-sympathetic PVN neuron significantly increased neuronal 
discharge in control rats with NS intake, but had less effect on AngII-salt HTN 
group indicating reduced SK channel activity.  Loss of SK channel function 
diminishes the mAHP and can lead to the loss of spike frequency adaptation in 
pre-sympathetic PVN neurons that help govern SNA. PVN-RVLM neurons from 
the AngII-salt group had a greater subthreshold depolarizing input resistance in 
response to ramp current injection and demonstrated an after-depolarizing 
potential (ADP) as opposed to the mAHP noted in control neurons.  Both the 
increased depolarizing input resistance and revealed ADP can potentially lead 
to increased excitability of PVN-RVLM neurons.144  The mechanism(s) whereby 
PVN SK channel dysfunction translates into elevated SNA remain to be fully 
determined.  PVN neurons have axon projections to several autonomic control 
centers including the RVLM, the nucleus tractus solitarii in the dorsal brain stem, 
and the spinal IML.105, 142, 179  Augmented excitability of the above pre-
sympathetic PVN neurons has the potential to increase SNA through multiple 
pathways within the SNS. 
The current study sought to determine the contribution of SK channels 
among PVN neurons to the sympathetic outflow in rats with AngII-salt HTN. The 
AngII-salt model HTN depends on the interaction of circulating AngII and dietary 
salt.72  Studies examining depressor responses to ganglionic blockade and 
whole-body norepinephrine spillover demonstrate that the neurogenic 
component of AngII-salt HTN depends on the level of dietary salt.74, 76, 178  A 
novel aspect of this study was our examination of the separate component of 
the AngII-salt model on PVN SK channel function.  Our data demonstrates that 
SSNA, RSNA and ABP responses to PVN apamin were not significantly 
different between rats with AngII-salt HTN and HS diet only, although 
the HS intake alone failed to increase ABP. These data suggest that 
perhaps dietary HS intake is a larger contributor to loss of SK channel 
function than circulating AngII.  The attenuated SNA and MAP 
responses to PVN SK channel blockade in rats consuming only a 
HS diet indicate that SK channel dysfunction may be a primary 
contributor to the elevated sympathetic outflow in rats with AngII-salt HTN. 
Despite a large body of epidemiological studies indicating that 
excess dietary salt is a primary contributor to essential HTN,180-182 the effects 
of a HS diet alone on neuronal excitability in the PVN remains largely 
undetermined.  HS intake alone is generally not sufficient to produce HTN in 
rats, however, it has been demonstrated that excess dietary salt has the 
ability to sensitize neural circuitry (pathways) within the sympathetic 
nervous system.183-186 Microinjection of apamin into the PVN of rats fed a 
HS diet elicited attenuated ABP and SNA responses compared to control 
rats fed a NS diet (Fig. 2.3).  This loss of SK channel function in the PVN 
of HS treated rats potentially primes the SNS through loss of spike 
frequency adaptation within pre-sympathetic PVN neurons.  Our data 
is of considerable interest when taken into account with previous 
studies demonstrating augmentations in excitability of the SNS after HS 
treatment, including one very recent study indicating that HS diet alone 
contributes to exaggerated SNA and ABP responses to various 
excitatory stimuli.187  The current study shows that a HS diet alone has the 
ability sensitize the neural circuitry in the PVN. The loss of SK channel 
function in the animals with HS intake provides a possible mechanism 
whereby a HS diet potentially alters membrane properties to influence 
the excitability of pre-sympathetic PVN neurons.  The sensitization of the 
PVN in the current study, and the RVLM in previous studies, occurs in the 
absence of HTN and provides a potential mechanism that can cause 
exaggerated SNS responses that contribute to neurogenic HTN.
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The effects of HS diet on neuronal membrane properties and excitability in 
cardiovascular control areas of the brain is of great interest and will require 
considerable attention in future studies. 
In order to determine the role AngII may have in altering PVN SK channel 
function, we examined responses to PVN apamin in subcutaneous AngII 
infused rats on a NS diet. Both SSNA and RSNA responses to PVN SK channel 
blockade were attenuated compared to control rats with a NS diet, although 
SSNA did not demonstrate statistical significance compared to NS control 
group.  In contrast, MAP responses to apamin were similar between the NS 
and AngII groups (Fig 2.3).  AngII alone appears to have less of a role in SK 
channel dysfunction than dietary HS intake and PVN apamin elicited a 
differential response between SSNA and RSNA.  This is of particular interest 
considering evidence indicating HS diet plays a larger role in the neurogenic 
component of AngII-salt HTN.73, 75  Loss of SK channel function due to HS 
diet likely plays a dominant role in the development of the neurogenic phase 
of AngII-salt HTN.  The mechanisms responsible for the different effect of 
PVN apamin on the SSNA and RSNA in AngII infused rats are not clear. 
The augmented sensory outflow from the circumventricular organs to the 
PVN due to systemic Ang II infusion may potentially target specific 
subpopulations of neurons leading to a differential SNA response to PVN 
SK channel blockade. Future studies are needed to investigate the 
mechanism for the differential between SNA and MAP responses to PVN 
apamin in rats with systemic administration of AngII. 
We have demonstrated a loss of SK channel function in the PVN in 
AngII-salt HTN utilizing both in vivo (Fig. 2.3) and in vitro approaches;144 
however, our data also indicates that SK1-3 channel protein is not 
different between NS control and AngII-salt HTN groups (Fig. 2.5). This 
potentially suggests that down-regulation of SK channels in AngII-salt HTN 
are due to loss of function as opposed to a difference in the number of 
channels expressed within the pre-sympathetic PVN neurons.  
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In addition, studies examining other regions of central nervous system 
have demonstrated SK channel expression in astrocytes188 and 
microglia,189, 190 and punched PVN tissue would not differentiate between cell 
types.   One recent study also has demonstrated no difference in SK channel 
expression level between Wistar-Kyoto and SHR supporting the notion that 
protein expression of SK channels is not altered in hypertensive rats143   It also 
showed that PVN SK channel dysfunction in SHR involves altered casein kinase 
II (CK2) activity that disrupts the Ca2+-calmodulin complex thereby reducing SK 
channel activity.143  Interestingly, the present study demonstrates that PVN 
microinjection of the SK channel activator, CyPPA has no influence on SNA and 
ABP in AngII-salt HTN.  CyPPA is known to significantly increase the Ca2+ 
sensitivity of SK channels191 and our data indicate that disruption of intracellular 
Ca2+ dynamics less likely contribute to the down-regulation of SK channel 
activity in the PVN in this chronic disease model of AngII-salt HTN. The 
mechanism(s) responsible for the reduced activity of SK channel in the PVN in 
rats with AngII-salt HTN require further attention in future studies.   
 This is the first study to demonstrate PVN SK channel dysfunction in rats 
with AngII-salt HTN utilizing an in vivo whole animal design.  While in vivo 
experimental designs preserve the substantial number of synaptic and reflex 
systems, potentially lost using in vitro preparations, there still remain limitations 
that must be recognized.  The current study required the use of anesthesia, 
which has the ability to influence cardiovascular responses.192  The effects of 
anesthesia on hemodynamic balance may potentially be reflected by the lack of 
HR differences in responses to PVN apamin among our treatment groups. 
Furthermore, there is a possibility that microinjected drugs spread outside the 
area of the PVN.  To exclude this possibility, we examined the diffusion of 
Chicago blue dye microinjected at the end of the experiment and present a 
composite demonstrating the largest diffusion area.  Our current data and a 
previously published report from our group indicate that the estimated diffusion 
area is confined close to the PVN.111   
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In summary, the present study suggests that reduced SK channel activity 
in the PVN contributes to Ang II-salt HTN.  Interestingly, reduced function of SK 
channels was present in the HS treated group in the absence of hypertension. 
This indicates that SK channel dysfunction is more than likely not secondary to 
the development of hypertension.  Lastly, in examining the individual 
contributions of systemic AngII treatment and dietary HS intake to reduce PVN 
SK channel activity, we demonstrate that dietary HS intake plays a larger role 
in PVN SK channel dysfunction compared to circulating AngII.  This data 
supports available evidence suggesting that the neurogenic component of Ang 
II-salt HTN is primarily dependent on the level of dietary salt.
2.5 Perspectives 
HTN is one of the main risk factors for the development of cardiovascular 
disease.  As such, determination of the mechanisms responsible for the 
development, and maintenance of HTN are of great importance in identifying 
targets for possible intervention in disease progression.  SK channels are 
unique, in that, blockade within the PVN elicits robust increases in SNA (~+250-
300%) and ABP (~+30 mmHg); demonstrating their significant involvement in 
inhibiting the pre-sympathetic PVN neuronal excitability/activity 111.  The present 
study supports the notion that intrinsic cellular mechanisms may play a 
significant role in AngII-salt HTN. Restoration of SK channel function potentially 
provides a significant target for attenuating the activation of sympathetic 
nervous system in neurogenic HTN. 
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Chapter 3. 
 
High Salt intake Augments Excitability of Pre-Sympathetic PVN 
Neurons through Dysfunction of Endoplasmic Reticulum Ca2+ 
Stores.2 
 
3.1 Introduction 
Elevated dietary salt intake is a major contributor to the pathogenesis of 
hypertension (HTN),193, 194 and estimates suggest that 25% of normotensive and 
50-60% of hypertensive individuals demonstrate salt-sensitivity.195, 196  Dietary 
salt exerts influence through several systems including renal, vascular, and 
hormonal actions;194 however, recent evidence indicates that the central 
nervous system (CNS) plays a prominent role in salt sensitive HTN through 
augmented sympathetic nerve activity (SNA).72, 74  Despite a wide body of 
evidence demonstrating the adverse cardiovascular effects of salt-sensitivity, 
the mechanism(s) whereby dietary salt augments SNA have yet to be fully 
elucidated. 
 The hypothalamic paraventricular nucleus (PVN) is a prominent 
regulatory center for the sympathetic nervous system. Pre-sympathetic neurons 
in the PVN receive excitatory synaptic input from the forebrain circumventricular 
organs98, 197 and project to the excitatory centers in the brain stem and spinal 
cord that drive SNA.105 Studies have demonstrated that enhanced PVN 
neuronal activity supports the augmented SNA in several models of neurogenic 
HTN.79, 121, 166   
 Augmented PVN neuronal activity in neurogenic HTN can arise through 
a variety of synaptic mechanisms including loss of GABA inhibition174 and 
augmented excitatory neurotransmitter signaling including glutamate and 
                                                 
2 The material contained in this chapter has been submitted to Circulation Research.  Copyright 
transfer agreement will become effective when accepted for publication. 
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angiotensin II.171  Furthermore, alterations of intrinsic membrane properties that 
influence PVN neuronal excitability also play an important role in neurogenic 
HTN.  Our lab198 and others143 have recently demonstrated that dysfunction of 
small conductance Ca2+-activated K+ (SK) channels contribute to neurogenic 
HTN.  The endoplasmic reticulum (ER) serves as a Ca2+ store and Ca2+ release 
from the ER is a prominent activator of SK channels.   
Recent reports indicate the brain ER stress is a mediator of neurogenic 
HTN, yet the mechanisms remain unclear.154, 199, 200  We tested the hypothesis 
that inhibition of the ER Ca2+ store with thapsigargin (TG) would augment SNA 
in vivo and neuronal excitability in vitro.  Additionally, we have previously 
demonstrated SK channel dysfunction and enhanced sympatheoexcitation in 
rats fed a 2% high salt (HS) diet;198 therefore, we further examined whether HS 
diet influences ER Ca2+ store function.  We hypothesized that HS intake would 
inhibit ER Ca2+ store function in pre-sympathetic PVN neurons, which may be 
an underlying mechanism to sympathoexcitation in salt-sensitive HTN.  Portions 
of this data have been presented in abstract form.201, 202 
 
3.2 Methods 
3.2.1 Animals 
Male Sprague-Dawley rats (n=61, 250-350g) purchased from Charles 
River Labs (Wilmington, MA) were housed in a temperature-controlled room 
(22-23C) with a 12:12 hour light-dark cycle.  Tap water was available ad libitum.  
Animals in the normal salt (NS) treatment group received standard laboratory 
chow (0.4% NaCl) ad libitum for 4 weeks whereas the HS treatment group was 
fed a 2% NaCl diet ad libitum for 4 weeks.  All experimental and surgical 
procedures were carried out under the guidelines of the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals with the approval of 
the Institutional Animal Care and Use Committee of Michigan Technological 
University. 
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3.2.2 Microinjection Experiment Preparation 
On the day of the experiment, rats were anesthetized with a mixture 
containing α–chlorolose (80 mg/kg) and urethane (800 mg/kg).  Body 
temperature was maintained at 37°C with a water circulating pad.  Catheters 
were implanted into the left femoral artery and vein in order to record arterial 
blood pressure (ABP) and administer drugs, respectively.  Heart rate (HR) was 
obtained from the R-wave of the electrocardiogram (lead I).  Rats were 
paralyzed with gallamine triethiodide, ventilated with O2-rich room air, and end-
tidal PCO2 was monitored and maintained within normal limits (33-40 mmHg).  
Adequate depth of anesthesia was determined by lack of withdrawal reflex to 
noxious foot pinch prior to paralysis and absence of pressor response to noxious 
foot pinch following paralysis with supplemental doses of anesthesia equal to 
10% of the initial dose given as needed.  All animals were allowed to stabilize 
at least 2 h following surgery.   
3.2.3 Recording of Sympathetic Nerve Activity (SNA) 
Rats were prepared for recording of splanchnic (SSNA) and renal 
(RSNA) SNA according to protocols previously described.111, 198  Briefly, a left 
flank incision was made and a left renal nerve and a postganglionic splanchnic 
nerve were separated from surrounding tissue.  Nerve bundles were mounted 
on separate silver wire electrodes (-mm diameter, A-M Systems) and covered 
with silicon-based impression material (Coltene, Light Body).  The signal was 
directed to an alternating current amplifier (P511, Grass Technologies) 
equipped with half-amplitude filters (band pass, 100-1,000 Hz) and a 60-Hz 
notch filter.  The processed signal was rectified, integrated (10-ms time 
constant), and digitized at a frequency of 5,000 Hz using a 1401 Micro3 analog-
to-digital converter and Spike 2 software (version 7.04, Cambridge Electronic 
Design, Cambridge, UK). 
3.2.4 Paraventricular Nucleus (PVN) Microinjection 
PVN microinjections were performed as previously described.111, 198 
Animals were placed in a stereotaxic head frame and the skull was leveled 
 
 
47 
 
between bregma and lambda.  A small section of the skull was removed in order 
to expose the dura, and a single-barreled glass microinjector pipette was 
lowered vertically into the PVN.  The stereotaxic coordinates used were as 
follows: 1.2 to 1.6 mm caudal to bregma, 0.5 mm lateral to midline, and 7.0 to 
7.2 mm ventral to dura.  After a 20-minute baseline period, thapsigargin (TG; 
100nl), an inhibitor of the endoplasmic reticulum (ER) Ca2+ ATPase (Tocris), or 
vehicle (DMSO; 100nl) was injected bilaterally into the PVN.  The micropipette 
was withdrawn between injections and bilateral injections were separated by 2 
minutes.  Variables were recorded for 2 hours following microinjection. 
3.2.5 Retrograde Labeling  
Five to 7 days prior to neuronal excitability recording, PVN neurons were 
retrogradely labeled from the ipsilateral rostral ventrolateral medulla (RVLM) as 
previously described.142, 144  Briefly, rats were anesthetized with isoflurane (3% 
in O2) and placed in a stereotaxic frame.  The cerebellum was exposed through 
a small burr hole and a glass micropipette was lowered into the pressor region 
of the RVLM (coordinates: −12.7 mm caudal to bregma, 1.8 mm lateral to 
midline and 8.9 mm below the skull). A pneumatic pump was utilized to inject 
Flurospheres (150nl, Life Technologies) into the RVLM.  Animals received daily 
subcutaneous injection of penicillin G (30,000 units) and meloxicam (1 mg/kg) 
for three days post-surgery.  Tracer location was verified histologically post-
mortem. 
3.2.6 Electrophysiology 
Five to seven days post-retrograde tracer injection, rats were 
anesthetized with isoflurane (3% in O2) and decapitated.  The brain was 
removed and chilled in ice-cold cutting solution containing (in mM): 206 sucrose, 
2 KCl, 2 MgSO4, 1.25 NaH2PO4, 26 NaHCO3, 1 CaCl2, 1 MgCl2, 10 d-glucose, 
and 0.4 ascorbic acid, osmolarity 295-302 mosmol L-1 measured with an 
osmometer (Wescor), pH 7.3-7.4, continuously gassed with 95:5 CO2:O2 to 
maintain pH and pO2.  A brain block was cut including the PVN region and 
affixed to a vibrating microtome (Leica VT 1000S; Leica, Nussloch, Germany). 
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Coronal sections of 250 µm thickness were cut, and the slices transferred to a 
holding container of artificial cerebral spinal fluid (ACSF) maintained at 30 °C, 
continuously gassed with 95:5 CO2:O2, containing (in mM): 125 NaCl, 2 KCl, 2 
MgSO4, 1.25 NaH2PO4, 26 NaHCO3, 2 CaCl2, 10 d-glucose, and 0.4 ascorbic 
acid (osmolality: 295–302 mosmol L−1; pH 7.3-7.4) and allowed to recover for 1 
hr.  Following recovery, slices were transferred to a glass-bottomed recording 
chamber and viewed through an upright microscope (E600FN, Nikon) equipped 
with DIC optics, epi-fluorescence, an infrared (IR) filter and an IR-sensitive video 
camera (C2400, Hamamatsu, Bridgewater, NJ).  Patch electrodes were pulled 
from borosilicate glass capillaries and polished to a tip resistance of 4–8 MΩ. 
Electrodes were filled with a solution containing (in mM) 135 K-gluconate, 10 
HEPES, 0.1 EGTA, 1.0 MgCl2, 1.0 NaCl, 2.0 Na2ATP, and 0.5 Na2GTP 
(osmolality: 280–285 mosmol L−1; pH 7.3).  Upon achievement of a gigaohm 
seal and whole cell configuration, cell capacitance, access resistance and 
resting membrane potential (Vm) were monitored to ensure stability.  Cells that 
met the following criteria were included in data set: Action potential amplitude ≥ 
50mV from threshold to the peak, input resistance (Rinput) larger than 0.5 GΩ 
when hyperpolarizing current injections of -20pA were delivered from a holding 
potential of -80mV, resting Vm negative to -50mV, and less than 20% change in 
series resistance during recording. 
3.2.7 Testing Neuronal Excitability 
Neuronal excitability from NS and HS rats was studied in current-clamp 
mode.  Vm was adjusted to -80mV by injecting continuous negative current, and 
a series of square-wave current injections was delivered in increments of +25 
pA, for a duration of 800 ms each.  To determine action potential voltage 
threshold (Vt) and depolarizing Rinput below Vt, ramp current injections (0.2 pA 
ms-1, 1,000 ms) were made from a potential of -80 mV.  Effects of ER Ca2+ store 
inhibition with TG on neuronal excitability were determined by comparing 
current evoked Vm and spike frequency responses under control conditions, and 
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following bath application of TG.  Responses were recorded from separate 
groups of NS and HS PVN-RVLM neurons. 
3.2.8 Western Blot measurements of SERCA Protein  
Western blot measurements for SERCA1, SERCA2 and SERCA3 
channel protein were performed as previously described.111 Brieﬂy, PVN from 
adult male rats (n=8 for the 0.4% NaCl control group, n = 8 for the 2% NaCl 
group) were removed and quickly frozen on dry ice. Frozen PVN tissue (100 
mg) was homogenized in 400 µl of buffer (50 mM Tris base, 1.0 mM EDTA, 150 
mM NaCl, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, and 1 mM 
PMSF, pH 7.4, Sigma) complete with protease inhibitors (0.1 mM leupeptin and 
0.3 mM PMSF, Sigma) and stirred for 30 min at 4°C. A centrifugal spin with 
12,000 rpm at 4°C was performed for 5 min. The supernatant was collected, 
and the protein concentration was determined in triplicate by a Bio-Rad DC 
protein assay kit at absorbance of 750 nm using BSA as a standard. Aliquots 
were stored at -80°C until analyzed, at which time the protein was separated 
using a SDS-polyacrylamide gel (10%) with electrophoresis followed by the 
electrophoretic transfer of proteins from the gel to a nitrocellulose membrane 
(Bio-Rad). Membranes were blocked with 5% nonfat milk for 1 h at room 
temperature, washed three times, and probed with the following primary 
antibodies: Goat anti-SERCA1 goat anti-SERCA2 antibody, or goat anti-
SERCA3 antibody (Santa Cruz Biotechnology) or with mouse anti-β Actin 
overnight at 4°C. After three 10-min washes in Trisbuffered saline-0.05% Tween 
20, membranes were incubated with donkey anti-goat horseradish peroxidase-
conjugated IgG or goat anti-mouse horseradish peroxidase-conjugated IgG 
secondary antibodies (Santa Cruz Biotechnology) for 1 h at room temperature 
and then detected with enhanced chemiluminescence. 
3.2.9 Chemicals 
All chemicals were obtained from Sigma-Aldrich (St Louis, MO) except 
for TTX (Tocris), TEA (Company), and TG (Tocris).  
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3.2.10 Data Analysis 
Summary data are expressed as mean ± SE.  SSNA and RSNA were 
determined as an average of the rectified, integrated signal.  Baseline values 
were obtained by averaging a 10-min window of data immediately prior to PVN 
microinjection.  Responses to PVN microinjection were obtained by averaging 
a 2-min segment centered on the maximal response quantified after subtraction 
of background noise obtained following bolus injection of the ganglionic blocker 
hexamethonium (30 mg/kg, IV).  Data were analyzed by one-way ANOVA and 
unpaired t-test where appropriate.  Post hoc analysis was performed with 
Newman-Keuls multiple-comparison test.  Differences were considered 
statistically significant at a critical value of P <0.05. 
3.3 Results 
3.3.1 Depletion of PVN ER Ca2+ stores Augments SNA and ABP  
In order to determine the contribution of the PVN neuronal ER Ca2+ 
stores in regulating SNA and ABP, we performed bilateral microinjection of TG 
into the PVN. PVN microinjection of TG elicited robust increases in SNA and 
ABP demonstrated in the raw trace data in Figure 3.1.  Maximum increases in 
SSNA, RSNA and mean arterial pressure (MAP) elicited by PVN TG (0.75 
nmol/100nl; n=6) were 92±6% (P<0.05 vs. vehicle), 72±6% (P<0.05 vs. vehicle), 
and 10±2mmHg (P<0.05 vs. vehicle), respectively as shown in Figure 3.2.  
Microinjection of TG (0.15nmol, n=4; 0.3nmol, n=5; 0.75nmol, n=6; 1.5nmol 
n=5) augmented SSNA, RSNA, and ABP in a dose dependent manner whereas 
bilateral microinjection of vehicle (DMSO, 100nL) into the PVN failed to elicit 
any significant response (P>0.05 vs baseline) in SNA, ABP or HR (Figs. 3.1 and 
3.2).  There were no significant differences in HR between any TG treatment 
dose and vehicle control (Fig. 3.2). Bilateral microinjection of TG (0.75nmol, 
100nl) outside of the PVN (~2.5mm lateral to midline) failed to produce any 
significant change in SSNA (10.5±8.1%), RSNA (4.4±7.1%) or ABP (1±1 
mmHg) respectively, indicating that the effects of TG appear to be site specific 
(Table 3.1).  In addition, the maximally effective dose of TG was injected into 
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the femoral vein in order to exclude the possible influence of peripheral actions.  
IV administration of TG had no significant effect on resting SSNA, RSNA, MAP 
and HR (Table 3.1). 
 
 
 
Figure 3.1 Representative raw tracings of splanchnic sympathetic nerve activity 
(SSNA), renal sympathetic nerve activity (RSNA) and arterial blood pressure 
(ABP) in response to paraventricular nucleus (PVN) microinjection of graded 
doses (vehicle, 0.15, 0.30, 0.75, 1.5 nmol) of the ER Ca2+ ATPase inhibitor 
thapsigargin (TG); HS-high salt diet (2%). 
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Figure 3.2 Summary data showing changes in SSNA, RSNA, mean arterial 
pressure (MAP), and heart rate (HR) in response to bilateral microinjections of 
varying doses of TG (vehicle, 0.15nmol, 0.3nmol, 0.75nmol, and 1.5nmol) into 
the PVN.  Graded concentrations of TG elicited a dose-dependent increase in 
recorded variables.  *P<0.05 vs. vehicle; †P<0.05 vs. 0.3nmol. 
 
 
Table 3.1 Effects of control injections on MAP, HR, SSNA, and RSNA in NS 
control rats. 
 
 
 
Values are mean ± SE; n = number of rats; SSNA, splanchnic sympathetic nerve 
activity; RSNA, renal  sympathetic nerve activity; MAP, mean arterial pressure; 
HR, heart rate; TG, thapsigargin; PVN, paraventricular nucleus.  
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3.3.2 HS Diet Disrupts PVN ER Ca2+ Store Function Contributing to 
Sympathoexcitation 
A major goal of this study was to determine whether disruption of ER 
Ca2+ store function contributes to sympathoexcitation.  Figure 3.3 left 
demonstrates representative raw tracings before, and after bilateral 
microinjection of TG from the NS treatment group.  Figure 3.3, right, 
demonstrates a representative response to bilateral PVN microinjection of TG 
(0.75nmol, 100nl) from the HS treatment group with a significantly attenuated 
response compared to NS.  Microinjection of 0.75nmol TG was utilized for 
comparison, as it was the minimum dose to elicit a maximum response in control 
rats (Fig. 3.1 & 3.2).  Maximum increases in SSNA (33±6%) and RSNA 
(26±5%), were significantly attenuated compared to NS (P<0.05 NS vs. HS) as 
demonstrated by summary data in Figure 3.4.  There were no significant 
differences in MAP (7±2 mmHg) and HR (5±3 bpm) between NS and HS 
treatment groups (Fig. 3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
 
 
 
 
 
 
Figure 3.3 Representative traces showing HR, SSNA, RSNA, and ABP 
responses to bilateral PVN microinjection of TG (0.75nmol) in a rat on a 0.4% 
normal salt (NS) diet (left), and a 2% high salt (HS) (right).  Bilateral PVN 
microinjection (100 nl each) of TG (arrowheads) markedly increased HR, SSNA, 
RSNA and ABP in a NS diet rat, whereas responses were attenuated in a rat 
fed a HS diet.  Avg, average; ∫, integrated. 
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Figure 3.4  Summary data showing peak changes in SSNA, RSNA, MAP and 
HR after bilateral PVN microinjection of TG (0.75nmol) in normal salt (NS) and 
high salt (HS) rats.  Note that SSNA and RSNA responses to PVN TG were 
significantly attenuated in HS rats compared to NS.  *P<0.05 HS vs. NS. 
 
 
3.3.3 HS Diet Disrupts ER Ca2+ Store Function Contributing to 
Augmented Excitability of PVN-RVLM Neurons 
Similar to previous reports, PVN-RVLM neurons lacked spontaneous 
discharge at resting Vm;142, 144 however, depolarizing current injections 
consistently evoked repetitive action potential firing. The role of the ER Ca2+ 
store in regulating excitability of PVN-RVLM neurons was examined by 
comparing the relationship between graded current injections and the evoked 
discharge in the absence and presence of TG (0.5 M). Figure 3.5A shows 
representative discharge responses to a 200pA depolarizing current pulse in 
the absence (top) and presence of the ER Ca2+ ATPase inhibitor, TG (bottom).  
Under control conditions, firing frequency in response to a 200pA current 
injection in neurons from NS rats (n=8, 22±2 Hz) was significantly lower than 
HS (n=7, 37±4 Hz, P<0.05 vs. NS control) (Fig. 3.5B & C, left vs. right).  
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Interestingly, inhibition of the ER Ca2+ store via bath application of TG 
significantly augmented firing frequency in the NS group (n=6, 30±4 Hz, P<0.05 
vs. NS control), but not HS (n= 6, 32±6 Hz, P>0.05 vs HS control) (Fig. 3.5C & 
D).  Furthermore, the slope of firing frequency in response to graded current 
injection was significantly greater in HS neurons (0.16±0.01, P<0.05 vs. NS 
control) compared to NS group (0.10±0.01) (Fig 5C & D).  Bath application of 
TG significantly increased the slope of firing frequency in response to graded 
current injections in NS group (0.14±0.01, P<0.05 vs NS control), yet had no 
significant effects on HS neurons (0.15±0.01, P>0.05 vs HS control) (Fig 3.5C 
& D). 
3.3.4 HS Disruption of ER Ca2+ Store Reduces Spike-Frequency 
Adaptation in PVN-RVLM Neurons 
We have previously demonstrated that loss of SK channel function in 
AngII-salt HTN augments excitability of PVN-RVLM neurons through loss of 
spike-frequency adaptation (SFA).144  Additionally, we recently reported SK 
channel dysfunction due to 2% HS diet treatment.198  Therefore, we examined 
whether the increased excitability of PVN-RVLM neurons due to ER Ca2+ store 
dysfunction was associated with a decrease in SFA.  Figure 3.6 Illustrates the 
slope of the inter-spike interval (ISI)-ISI number curve over trains of action 
potentials in response to a 200pA current injection in PVN-RVLM neurons from 
NS (left) and HS (right) rats.  The slope of the linear fit of the ISI-ISI number 
curve was significantly (P<0.05) greater in NS (2.2±0.2, P<0.05 vs. HS) 
compared to HS (1.5±0.1) indicating that spike-frequency adaptation is reduced 
in HS neurons under control conditions (Fig. 3.6B).  Additionally, TG significantly 
decreased the slope of ISI-ISI number curve in NS (1.1±0.1, P<0.05 vs. NS 
control) group indicating that inhibition of the ER Ca2+ store reduces spike-
frequency adaptation (Fig. 3.6B, left).  Interestingly, slope was unchanged in the 
HS group (1.3±0.1, P>0.05 vs. control) following application of TG (Fig. 3.6B, 
right).  Bath application of TG (0.5 M) had no significant effects on any passive 
membrane properties (Table 3.2). 
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Figure 3.5 Effects of ER Ca2+ store inhibition with TG on excitability of PVN-
RVLM neurons from NS left and HS right rats.  A. Voltage traces illustrating 
neuronal excitability in response to a 200pA current injection in PVN-RVLM 
neurons from NS rats in the absence (top, control) and presence (bottom) of the 
ER Ca2+ ATPase inhibitor TG.  B. Representative responses of PVN-RVLM 
neurons from HS rats to 200pA current injection in the absence (top) and 
presence (bottom) of TG.  C. Linear response demonstrating the slope of firing 
frequency in response to graded current injection (0-200pA) in PVN-RVLM 
neurons in the absence and presence of TG in NS (left) and HS (right) neurons. 
TG increased firing frequency in the NS group, but not HS.  Note that firing 
frequency in response to 200pA depolarizing current injection was increased in 
HS (right) compared to NS (left). D. Summary data showing slope of firing 
frequency in response to graded current injection before and after bath 
application of TG in NS (left) and HS (right) rats.  Inhibition of the ER Ca2+ store 
with TG augmented the slope in NS (left), but not HS (right) neurons.  Note that 
in control conditions, the slope was significantly greater in HS neurons. NS-
normal salt; HS-high salt; TG-thapsigargin. †P<0.05 NS vs. NS –TG; &P<0.05 
NS vs. HS; *P<0.05 NS vs. NS-TG; #p<0.05 NS vs. HS. 
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Figure 3.6 Effects of ER Ca2+ store inhibition with TG on spike-frequency 
adaptation in PVN-RVLM neurons.  A. Linear response of inter-spike interval 
(ISI)-ISI number over trains of action potentials in response to 200pA current 
injection in PVN-RVLM neurons from NS left and HS right treatment groups 
before and after bath application of TG. B. Summary data showing slope of the 
ISI-ISI number response to 200pA current injection was diminished in HS rats 
compared to NS revealing greater spike frequency adaptation in NS neurons.  
TG attenuated the slope of ISI in NS (left), but not HS (right) neurons.  NS-
normal salt; HS-high salt; TG-thapsigargin. *P<0.05 NS vs. NS-TG; #p<0.05 NS 
vs. HS. 
 
Table 3.2 Passive membrane properties of PVN-RVLM neurons. 
 
 
Values are mean ± SE, n = number of neurons, Vm, resting membrane potential; 
Cm, membrane capacitance; Rinput, depolarizing input resistance; Vt, sub-
threshold of membrane potential to fire action potential. 
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3.3.5 Comparison of PVN SERCA Protein Expression  
In order to further explore potential mechanisms for ER Ca2+ store 
dysfunction due to HS diet, we compared protein expression (Western blot 
analysis) of SERCA1-3 in the hypothalamic PVN between rats on a NS diet 
(0.4% NaCl, n=8) for 4 weeks, or a HS salt diet (2% NaCl, n=8) for 4 weeks.  
Contrary to our hypothesis, expression of SERCA1 was significantly increased 
by a HS diet (Fig. 3.7). SERCA2 expression tended to be increased by HS diet; 
however, the difference did not reach statistical significance. SERCA3 was not 
detected in the PVN (data not showed here). 
 
Figure 3.7 Expression of SERCA1 and SERCA2 in the PVN. A: Western blot 
analysis showing protein expression of SERCA1 and SERCA2 in PVN in 
animals with either NS (0.4% NaCl) control or HS (2% NaCl) group.  B: 
Summary data showing HS intake significantly increased protein expression of 
SERCA1 in the PVN. SERCA2 levels tended to be increased, but the difference 
did not demonstrate statistical significance.  All values were normalized to β 
actin. *P<0.05 vs. NS control. 
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3.3.6 Histology 
Injection sites were marked with 2% Chicago blue dye (100nl).  Coronal 
slices through the rostral caudal plane encompassing the PVN were examined 
to ensure microinjections were confined to the PVN as previously described by 
our laboratory.198 Figure 3.8 shows the composite diffusion area of injected dye 
compiled by overlying brain slices from separate rats to demonstrate the 
outermost diffusion area.  Distribution of injected dye was largely confined to 
the area encompassing the PVN. 
 
Figure 3.8 Schematic drawings of coronal sections throughout the rat 
hypothalamus.  A: Shaded area indicates spread of injected dye used to mark 
the injection sites in the bilateral PVN.  The shape of each area was determined 
by overlaying tracings of the outermost diffusion area of injected dye (100 nl) 
through the rostral-caudal plane of the PVN.  AH, anterior hypothalamic area; 
3V, third cerebral ventricle; RCh, retrochiasmatic area; MPO, medial preoptic 
nucleus; opt, optic tract; SOX, supraopticdecussation; StHy, striohypothalamic 
nucleus. 
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3.4 Discussion 
The PVN is a key regulatory center for SNA, and disinhibition of PVN 
neurons contributes to the augmented sympathetic outflow in neurogenic HTN.   
Here, we demonstrate the importance of PVN ER Ca2+ store function in 
regulating SNA and ABP in vivo, and neuronal excitability in vitro. Bilateral PVN 
microinjection of TG, the ER Ca2+ATPase inhibitor known to deplete the ER Ca2+ 
store,203 augmented SSNA, RSNA and MAP in a dose-dependent manner 
demonstrating that the ER Ca2+ store plays a significant role in modulating SNA 
and ABP.  Interestingly, sympathoexcitatory responses to PVN TG were 
significantly blunted in rats fed a 2% HS diet for 4 weeks indicating dysfunction 
of the ER Ca2+ store.  Importantly, we also demonstrate augmented neuronal 
excitability in PVN neurons with axon projections to the RVLM (PVN-RVLM) in 
rats fed a HS diet. Bath application of TG significantly augmented excitability of 
PVN-RVLM neurons in rats with a NS diet yet had no significant effect in animals 
with a HS diet.  These results indicate that loss of ER Ca2+ store function likely 
plays a role in the augmented neuronal excitability due to chronic HS intake.  
Finally, PVN protein expression of SERCA1 and SERCA2 were upregulated in 
HS rats, which suggests that compensatory mechanisms have been evoked to 
oppose the dysfunction of ER Ca2+ stores in response to chronic HS intake. 
Therefore, we conclude that dysfunction of the ER Ca2+ store in pre-sympathetic 
PVN neurons represents a novel mechanism contributing to sympathoexcitation 
evoked by HS intake. 
 The sympathetic nervous system plays a prominent role in the 
pathogenesis and maintenance of salt-sensitive HTN.204 HTN induced by 
chronic infusion of AngII combined with a 2% HS diet (AngII-salt) is a well-
established animal model of salt-sensitive HTN.72 Previous studies using 
chronic protocols have established that sympathetic activation is largely 
responsible for HTN in this model.73, 76, 77, 205 Furthermore, the neurogenic 
aspect of the AngII-salt model is primarily mediated by dietary salt.74, 75 Our lab 
has recently demonstrated that dysfunction of SK channels in the PVN 
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contributes to sympathoexcitation in AngII-salt HTN using both in vivo and in 
vitro approach.144, 198 Interestingly, we showed that SK channel dysfunction is 
present in normotensive rats fed a 2% HS diet.198 Importantly, in the present 
study, we demonstrate that excitability of PVN-RVLM neurons is augmented by 
2% HS diet.  Taken together with previous results, our current data indicate that 
HS-induced augmented excitability of pre-sympathetic PVN neurons in not 
secondary to the development of HTN and likely represents an important 
primary mechanism contributing to sympathoexcitation induced by HS intake.  
 Enhanced neuronal activity among PVN neurons has been noted in a 
variety of cardiovascular diseases characterized by high sympathetic outflow 
including heart failure and HTN.121, 165 Recently, Bardgett et al demonstrated 
that acute inhibition of the PVN via microinjection muscimol significantly 
attenuated SNA and MAP in AngII-salt HTN. This provides strong evidence that 
PVN neuronal activity is required to maintain the augmented sympathetic 
outflow and blood pressure in this model of neurogenic HTN.79 Less is known 
about the cellular mechanisms that are responsible for the augmented PVN 
neuronal activity in neurogenic HTN.  The present study is the first to 
demonstrate the importance of ER Ca2+ stores in regulating PVN neuronal 
activity/excitability. 
 Depletion of ER Ca2+ store via bilateral microinjection of TG, an inhibitor 
of the ER Ca2+ ATPase, significantly augmented SSNA, RSNA and MAP.  
Importantly this response demonstrated dose dependence helping to rule out 
non-specific drug actions that potentially contribute to sympathoexcitation.  
Additionally we performed control experiments by delivering TG via IV catheter, 
and microinjection outside the PVN (2.5mm lateral to midline) in separate 
experiments.  Neither of these two control deliveries resulted in a significant 
change in SNA or ABP, which further demonstrates that action of the drug in 
our acute experimental model likely depends on actions within the PVN.  
Furthermore, spread of injected dye (100nl) following experiments was largely 
confined to the PVN.  PVN neurons influence sympathetic activity through axon 
projections to the prominent autonomic control centers such as the RVLM, the 
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spinal IML and the nucleus tractus solitarri.105, 179 Sympathoexcitatory 
responses to PVN TG are likely mediated through these projections to 
significantly influence ongoing levels of SNA. 
 In order to further investigate the underlying cellular mechanisms of ER 
Ca2+ stores in the PVN in regulating SNA and ABP, we utilized whole-cell 
current clamp to examine excitability of pre-sympathetic PVN-RVLM neurons 
identified by retrograde labelling under brain slice preparation.  Inhibition of the 
ER Ca2+ store via bath application of TG augmented excitability of PVN-RVLM 
neurons (Fig. 3.5). TG is an inhibitor of the ER Ca2+ ATPase which pumps Ca2+ 
into the ER to maintain high Ca2+ levels within the ER and preserves intra-
neuronal Ca2+ homeostasis.203 Therefore, inhibition of the ER Ca2+ ATPase by 
TG would eventually result in a depletion of the ER Ca2+ store which likely 
contributes to the dysfunction of Ca2+ activated K+ channels including SK 
channels and augmented neuronal excitability.158 This possibility is supported 
by our previous report showing that Ca2+ free bath application significantly 
diminished SK currents and blockade of SK channels increased excitability 
among PVN-RVLM neurons.142 Our recent findings showing that Ca2+ chelators 
BAPTA and EGTA, significantly increased both in vivo SNA and in vitro neuronal 
excitability of PVN-RVLM neurons also support this possibility.206 Moreover, the 
present study demonstrates that TG inhibits spike frequency adaptation (SFA) 
among PVN-RVLM neurons contributing to increased excitability (Fig. 3.6), 
which lends further support to the possibility since we previously reported that 
reductions in SFA contribute to the increased excitability of PVN-RVLM neurons 
following SK channel blockade. 142 Whether reduced SK current underlie the 
mechanisms of TG elicited increases in excitability of PVN-RVLM neurons 
remains further study in the future. 
The ER is an important regulator of intracellular Ca2+ hemostasis.  Here, 
we also present a novel mechanism whereby HS diet disrupts ER Ca2+ stores 
in the pre-sympathetic PVN neurons.  SSNA, RSNA and MAP responses to 
PVN microinjection of TG were significantly attenuated in HS rats indicating that 
Ca2+ store function is altered by HS treatment.  In order to further explore 
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mechanisms whereby HS diet contributes to augmented activity/excitability of 
PVN neurons, we examined PVN-RVLM neurons with whole-cell patch clamp 
techniques.  Interesting, we found that firing frequency in response to a 200pA 
current injection is significantly augmented in HS neurons.  Additionally, the 
slope of the linear response to graded current injections is significantly 
augmented in HS neurons.  We have previously reported that excitability of 
PVN-RVLM neurons is augmented in AngII-salt HTN144 and results from the 
present study further indicate that excitability of PVN-RVLM neurons is 
augmented by HS diet alone in the absence of HTN.  Interestingly, bath 
application of TG had no significant effect on either firing frequency in response 
to 200pA current injection, or the slope of firing frequency in response to graded 
current injection in HS rats indicating that dysfunction of the ER Ca2+ store likely 
contributes to the augmented PVN neuronal excitability in HS rats.  In order to 
explore possible mechanisms for the augmented excitability of PVN-RVLM 
neurons due to HS intake, we compared SFA in NS and HS neurons. SFA was 
significantly attenuated in HS neurons indicated by a reduction in the slope of 
ISI-ISI number curve and bath application of TG did not significantly alter SFA 
in HS neurons. SK channel is Ca2+ dependent and a primary mediator of 
SFA.141, 207 Therefore, we expect that the reduced SFA in HS neurons could be 
due to reduced SK channel activation through diminished ER Ca2+ signaling. 
SERCA2 is ubiquitously expressed throughout the CNS, whereas 
SERCA3 has only demonstrated expression in Purkinje fibers of cerebellum; 
however, little is known regarding SERCA1 expression in the CNS.208, 209 The 
present study has demonstrated a disruption of ER Ca2+ stores in the PVN in 
animals with a HS diet using both in vivo and in vitro approaches. Initially, we 
have hypothesized that a down-regulation of SERCA1-2 might contribute to the 
dysfunction of ER Ca2+ stores. Surprisingly, our data indicates that protein 
expression of SERCA1 is significantly augmented and SERCA2 levels tended 
to be increased in punched PVN tissue from HS rats (Fig. 3.7). Our data 
demonstrating altered ER Ca2+ regulation in response to HS Diet indicates 
dysfunction of the ER Ca2+ ATPase and we speculate that the augmented 
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SERCA1-2 expression may be a compensatory mechanism to maintain ER 
Ca2+ homeostasis.  SERCA function and expression remains largely to be 
explored in the CNS and we are the first to report the expression of SERCA1-2 
protein in the PVN.  
SERCA pumps are widely expressed throughout the body, but little is 
known regarding altered expression levels in the CNS due to pathological 
conditions.  Studies in cardiomyocytes indicate that catecholamines increase 
SERCA2 expression.210, 211 further studies in cardiomyocytes demonstrate that 
SERCA2 expression can be augmented through the anti-apoptotic protein, Bcl-
2.212 SERCA pumps are highly conserved throughout a variety of cell types and 
future studies are needed to examine if a similar protective mechanism exists 
in PVN neurons due to HS intake.  It’s also important to note that punched PVN 
tissue contains both magnocellular and parvocellular neurons, as well as 
astrocytes and glial cells. Therefore, we are cautious in our interpretation of the 
data since the diverse population of neural cells in the PVN that may have 
functions and projections that have no influence on sympathetic outflow.    
In the current study, we have examined ER Ca2+ store function through 
inhibition of ER Ca2+ uptake with TG, an inhibitor of the ER Ca2+ ATPase.  Future 
investigation is required to determine if alterations in release of ER Ca2+ 
contributes to augmented neuronal excitability due to HS diet.  Release of ER 
Ca2+ is primarily mediated through two distinct types of ligand gated Ca2+ 
channels including the inositol 1,4,5-triphosphate receptor (InsP3R) and the 
ryanodine receptor (RyR).  Release of ER Ca2+ through the InsP3R is activated 
primarily through synaptic activity whereas RyR activation occurs primarily 
through Ca2+ induced Ca2+ release (CICR).156 During trains of action potentials, 
Ca2+ entry through voltage dependent Ca2+ channels (VDCCs) stimulates CICR 
from RYR, resulting in a significant elevation of cytoplasmic Ca2+.158 CICR 
during action potentials is a key activator of SK channels, and therefore, can 
significantly influence neuronal excitability.207 Whether HS diet induces 
alterations in ER Ca2+ release in the pre-sympathetic PVN remains to be 
determined. 
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3.5 Perspectives 
 HTN is a major risk factor for cardiovascular disease and the majority of 
cases demonstrate sensitivity to dietary salt.  While salt-sensitive HTN depends 
on complex interactions involving multiple body systems including renal and 
vascular, recent studies have demonstrated the importance of the SNS.  Due to 
the prevalence of essential HTN, identification of new treatment targets is 
imperative to the overall health of society.  The present study identifies a novel 
mechanism whereby disruption of Ca2+ homeostasis in the ER contributes to 
enhanced sympathoexcitation and augmented neuronal excitability due to HS 
diet.  In the present study, PVN microinjection of TG augmented SNA and ABP 
in vivo, and neuronal excitability in vitro demonstrating the contribution of the 
ER in regulating sympathetic outflow.  In contrast, sympathoexcitatory 
responses to PVN TG were significantly attenuated in HS rats and bath 
application of TG had no significant influence on excitability of PVN-RVLM 
neurons indicting dysfunction of the ER Ca2+ store.  The ER is a new and novel 
treatment target due to its involvement in a multitude of cellular process and we 
are only beginning to understand the role it plays in mediating neuronal 
excitability and sympathetic activation.  Future studies are needed to elucidate 
the molecular mechanisms that underlie HS diet induced ER dysfunction. 
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Chapter 4.   
Summary, Limitations, and Future Directions 
 
4.1 Summary 
Cardiovascular disease is the leading cause of death in the United 
States.1  Reducing the incidence of CVD would have a significant impact on the 
overall health of the population, and in many cases, improve quality of life.  HTN 
is also very prevalent in the United States and is a major risk factor for the 
development of CVD.1  Evidence suggests that approximately 25% of 
individuals with normal blood pressure, and 50-60% of individuals diagnosed 
with HTN demonstrate sensitivity to salt.195, 196  The CNS plays a major role in 
the pathogenesis and maintenance of salt-sensitive hypertension through 
augmented activity of the SNS.67, 72  The overall goal of our research is to identify 
central neural mechanisms that contribute to sympathoexcitation due to HS 
intake, in order to develop new targets for the treatment of salt-sensitive HTN. 
Salt-sensitive hypertension involves excess activation of the SNS.  
Neuronal activity in the hypothalamic PVN is augmented in AngII-salt HTN and 
PVN neuronal activity is required to maintain the high SNA and ABP in this 
model of salt-sensitive HTN.79  Previous work from our lab demonstrates that 
SK channel dysfunction is a key contributor to augmented excitability among 
PVN-RVLM neurons.144  In study 1, we demonstrate that sympathoexcitatory 
responses to PVN SK channel blockade are attenuated in AngII-salt 
hypertension.  Furthermore, we report that SK1-3 protein levels in punched PVN 
tissue were not different between normotensive control and AngII-salt HTN. 
These results indicate that dysfunction of SK channels contributes to 
sympathoexcitation in AngII-salt HTN.  SK channels are powerful negative 
feedback regulators of excitability, and normally function to suppress PVN 
neuronal excitability.142  Interestingly, we also demonstrate SK channel 
dysfunction in HS only rats that are normotensive.  These results indicate that 
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dietary salt likely plays a dominant role in down-regulating SK channel function 
in the PVN. 
In study 1 we demonstrate SK channel dysfunction in the PVN of AngII-
salt hypertensive rats.  Additionally, SK channel dysfunction has been reported 
in IML projecting PVN neurons in spontaneously hypertensive rats as well.143  
Therefore, we sought to examine mechanisms that contribute to PVN SK 
channel dysfunction.  Ca2+ release from the ER Ca2+ store during action 
potentials is a prominent activator of SK channels.207  Recent reports indicate 
that brain ER stress plays a role in the pathogenesis of hypertension 
characterized by high sympathetic outflow.154, 199, 200  In study 2 we examined 
the functional role of the endoplasmic reticulum in regulating neuronal 
excitability in vitro and sympathetic nerve activity and blood pressure in vivo.  
We demonstrate that inhibition of ER Ca2+ store function with PVN 
microinjection of TG augments sympathetic nerve activity and blood pressure.  
In addition, bath application of TG significantly augments excitability of PVN-
RVLM neurons.  Interestingly, excitability of PVN-RVLM neurons was 
significantly augmented in HS treated rats compared to control, and we further 
demonstrate that dysfunction of the ER Ca2+ store contributes to the augmented 
neuronal excitability.  Finally, SFA is primarily mediated by Ca2+ activated K+ 
channels including SK, and we report that SFA is diminished in HS rats.  
Furthermore, bath application of TG significantly diminished SFA in control rats 
yet had no effect in the HS treatment group.  These results indicate that loss of 
ER Ca2+ store function due to HS intake contributes to augmented neuronal 
excitability likely through diminished function of Ca2+ activated K+ channels. 
 
4.2 Limitations  
 Several limitations must be recognized for the preceding studies.  All of 
our whole animal studies utilized anesthetized animal preparations.  Anesthesia 
could potentially impact the cardiovascular responses to PVN microinjection of 
apamin or TG.192  Future studies will employ telemetry recordings of SNA and 
 
 
69 
 
ABP in order to elucidate the impact of SK channel function in conscious, free-
moving animals.  We utilize pharmacological agents including ion channel and 
transporter blockers in these studies, and it’s important to recognize that these 
agents may have non-specific effects.  In a previous study we performed control 
experiments with apamin including determination of a dose dependent 
response, microinjection outside of the PVN to determine site specificity, as well 
as IV injection to rule out peripheral actions of the apamin.111  Furthermore, in 
study 1, we marked injection sites with Chicago Blue dye and examined 
distribution of the dye to confirm that distribution was primarily within the PVN.  
In study 2 we also examined the dose dependent response of TG in order to 
find the minimum dose that elicits a maximum response in SNA and ABP and 
rule out potential non-specific effects.  Additionally, we performed control 
injections outside of the PVN (2.5mm lateral to midline), as well as IV injection 
of the minimum effective dose to rule out peripheral actions.  Additionally, we 
confirmed that spread of injected dye following experiments was largely 
confined to the PVN. 
 It’s important to note that both of the primary drugs we utilized in study 1 
and study 2 cannot be used in human studies.   The methodology utilized in the 
current research involves targeted delivery to specific brain areas that are not 
accessible in humans. Apamin is a component of bee venom and acts as a 
neurotoxin.  Apamin administered peripherally in sub-lethal doses results in 
seizures in mice, and marked changes in neuronal structure in neuronal cultures 
during chronic bath application.213, 214  Chronic application of TG induces brain 
ER stress in live animals and cellular apoptosis through diminished ER Ca2+ 
handling both in vivo and in vitro.149, 154, 203  The goal of our research is to 
ultimately develop new treatment strategies in humans and alternative 
approaches will have to be developed for studies involving human intervention. 
 It’s also important to recognize that other brain regions besides the PVN 
contribute to the high sympathetic outflow in salt-sensitive HTN.  The CVO’s 
including the OVLT and SFO contribute to salt-sensitive HTN.215, 216  
Additionally, the RVLM is a key driver of tonic SNA.7  Evidence demonstrates 
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that HS intake augments angiotensinergic activity within the RVLM contributing 
to augmented sympathetic outflow.183, 217  Further information suggests that 
excess salt intake sensitizes neurons in the RVLM contributing to exaggerated 
SNA and ABP responses to excitatory and inhibitory stimuli.184, 218  Recent 
evidence indicates that increases in cerebrospinal (CSF) fluid Na+ concentration 
activates RVLM neurons to produce exaggerated elevations in SNA.219  Our lab 
examines alterations in the PVN that contribute to salt-sensitive HTN; however, 
we recognize that other CNS sites likely provide significant contributions to salt-
sensitive hypertension.  
 
4.3 Future Studies 
Our goal is to elucidate central neural mechanisms responsible for the 
high sympathetic outflow due to HS intake.  We have demonstrated that PVN 
SK channel dysfunction contributes to augmented excitability of PVN-RVLM 
neurons in vitro, and sympathoexcitation in vivo.  We seek to test the overall 
hypothesis that HS intake augments excitability of PVN neurons making them 
susceptible to further stimuli such as AngII or stress to induce HTN. We 
demonstrate in study 1 that HS intake induces SK channel dysfunction even in 
the absence of HTN.  In addition, in study 2 we demonstrate augmented 
excitability of PVN-RVLM in HS rats that have not developed HTN.   
Ongoing studies in our lab demonstrate SK channel dysfunction in Dahl 
salt-sensitive rats.  Dahl rats are an ideal model to perform a treatment study in 
that they only require high salt food to become hypertensive.  We plan to 
perform continuous infusion of an SK channel positive modulator in the PVN of 
Dahl salt-sensitive rats.  We hypothesize that maintaining SK channel function 
in the PVN will attenuate hypertension.  We will further explore SK channel 
function utilizing viral vectors to knock out, or overexpress SK channels in Dahl 
salt-sensitive rats in order to determine their contribution in a chronic model. 
 We further seek to identify the mechanism(s) responsible for SK channel 
dysfunction due to HS intake.  In study 2 we demonstrate the contribution of the 
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ER in regulating neuronal excitability in vitro, and SNA and ABP in vivo.  We 
demonstrate that dysfunction of the ER Ca2+ store augments PVN neuronal 
excitability likely through less activation of Ca2+ activated K+ channels including 
SK.  The ER is only one source of Ca2+ that activates SK channels (Fig 1.8) and 
we have only used a blocker of ER Ca2+ uptake.  Further studies are required 
to examine release of ER Ca2+ from IP3 and RYR sources.  Additionally, 
ongoing studies in the lab are examining the interaction of NMDA glutamate 
receptors, AT1R’s, and VDCC’s with SK channels.  Future studies will also 
examine whether alterations in the Ca2+-calmodulin complex contribute to SK 
channel dysfunction in AngII-salt HTN.  
 
4.4 Conclusions 
 This dissertation reports novel findings that potentially provide new 
treatment targets for salt-sensitive HTN.  First, we report that SK channel 
dysfunction in the PVN is a key contributor to the augmented sympathetic 
outflow in AngII-salt HTN.  Additionally, we report that HS intake likely plays a 
dominant role in reducing SK channel function in the PVN.  Secondly, 
demonstrate the importance of the ER Ca2+ store in regulating PVN neuronal 
excitability in vitro, and SNA and ABP in vivo.  Finally we report that the 
dysfunction of the ER Ca2+ store contributes to augmented PVN neuronal 
excitability due to HS diet, likely through reduced activity of Ca2+ activated K+ 
channels including SK.  These finding provide new and valuable information into 
the central neural mechanisms contributing to salt-sensitive HTN. 
 
 
 
72 
 
 
Figure 4.1 Summary of mechanisms contributing to sympathoexcitation in 
Study 1 and Study 2.  AngII-salt HTN involves reduced SK channel function in 
the PVN (Study 1).  Diminished ER Ca2+ store function contributes to 
augmented PVN neuronal excitability (Study 2).  Augmented excitability of PVN 
neurons increases sympathetic nerve activity targeting the heart, kidneys and 
vasculature to increase arterial blood pressure.  
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Appendix A. Raw Data for Study 1. 
 
Table A.1 Raw data for Splanchnic and Renal Sympathetic Nerve Activity for 
Angiotensin II-Salt treatment group. 
 
 SSNA RSNA 
Rat 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
1 0.086 0.107 32.881 0.023 - - - - 
2 0.019 0.021 20.119 0.007 - - - - 
3 0.064 0.068 8.990 0.023 0.013 0.013 -5.318 0.006 
4 - - - - 0.025 0.035 50.139 0.005 
5 0.054 0.060 22.809 0.024 - - - - 
6 0.080 0.117 97.409 0.041 - - - - 
7 - - - - 0.062 0.102 105.789 0.024 
8 - - - - 0.049 0.040 -18.367 - 
9 - - - - 0.061 0.062 1.631 - 
10 - - - - 0.062 0.086 37.180 - 
11 - - - - 0.050 0.053 6.219 - 
 
 
Table A.2 Raw data for Mean Arterial Blood Pressure and Heart Rate for Angiotensin 
II-Salt treatment group. 
 
 MAP HR 
Rat 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
1 - - - 309 293 -13 
2 145 143 -2 396 369 -27 
3 139 131 2 - - - 
4 - - - 424 479 55 
5 129 146 17 401 354 -47 
6 125 170 45 394 354 -47 
7 124 136 12 332 330 -2 
8 143 143 0 391 388 -3 
9 117 122 5 414 442 28 
10 - - - 482 487 5 
11 - - - 413 423 10 
 
SSNA-Splanchnic Sympathetic Nerve Activity; RSNA-Renal Sympathetic Nerve 
Activity; MAP-Mean Arterial Pressure; HR-Heart Rate. 
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Table A.3 Raw data for Splanchnic and Renal Sympathetic Nerve Activity for 
Angiotensin II treatment group. 
 
 SSNA RSNA 
Ra
t 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
1 0.058 0.135 245.687 0.027 - - - - 
2 0.121 0.170 68.837 0.049 0.008 0.011 64.662 0.004 
3 0.091 0.214 374.618 0.059 0.015 0.029 138.198 0.005 
4 0.048 0.101 145.504 0.011 0.030 0.052 131.481 0.014 
5 - - - - - - - - 
6 - - - - 0.044 0.040 -12.773 0.018 
7 0.037 0.051 73.196 0.018 0.040 0.051 53.702 0.019 
 
 
Table A.4 Raw data for Mean Arterial Blood Pressure and Heart Rate for Angiotensin 
II treatment group. 
 
 MAP HR 
Rat 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
1 121 150 29 418 428 10 
2 115 154 39 401 413 12 
3 118 159 41 375 413 38 
4 125 155 30 - - - 
5 101 140 39 367 372 5 
6 87 121 34 303 329 26 
7 90 118 28 321 326 5 
 
 
SSNA-Splanchnic Sympathetic Nerve Activity; RSNA-Renal Sympathetic Nerve 
Activity; MAP-Mean Arterial Pressure; HR-Heart Rate. 
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Table A.5 Raw data for Splanchnic and Renal Sympathetic Nerve Activity for High 
Salt treatment group. 
 
 SSNA RSNA 
Ra
t 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
1 0.087 0.184 192.09 0.037 0.019 0.026 47.45 0.005 
2 0.065 0.098 125.40 0.039 - - - - 
3 0.026 0.044 95.94 0.008 0.099 0.115 38.29 0.056 
4 - - - - 0.010 0.013 63.88 0.006 
5 0.021 0.023 44.28 0.017 - - - - 
6 0.013 0.031 198.94 0.004 0.034 0.064 160.20 0.016 
7 0.074 0.084 51.91 0.055 0.045 0.048 15.82 0.030 
8 0.043 0.071 180.64 0.028 0.017 0.021 58.68 0.011 
9 0.055 0.094 114.62 0.021 0.051 0.073 55.87 0.011 
 
Table A.6 Raw data for Mean Arterial Blood Pressure and Heart Rate for Angiotensin 
II treatment group. 
 
 MAP HR 
Rat 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
1 - - - 385 342 -43 
2 81 118 37 354 392 38 
3 127 130 3 365 388 23 
4 114 131 17 359 349 -10 
5 99 107 8 343 352 9 
6 102 134 32 355 374 19 
7 - - - - - - 
8 120 153 33 335 395 60 
9 123 132 9 318 343 25 
 
SSNA-Splanchnic Sympathetic Nerve Activity; RSNA-Renal Sympathetic Nerve 
Activity; MAP-Mean Arterial Pressure; HR-Heart Rate. 
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Table A.7 Raw data for Splanchnic and Renal Sympathetic Nerve Activity for Normal 
Salt treatment group. 
 
 SSNA RSNA 
Rat 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
1 0.021 0.058 384.52 0.011 - - - - 
2 0.021 0.046 344.28 0.014 - - - - 
3 0.022 0.057 337.56 0.012 0.025 0.052 214.76 0.012 
4 0.042 0.068 266.96 0.032 - - - - 
5 - - - - 0.038 0.056 211.55 0.033 
6 - - - - 0.039 0.046 162.70 0.036 
7 - - - - 0.041 0.055 200.42 0.033 
8 - - - - 0.042 0.056 209.79 0.034 
9 0.030 0.046 105.06 0.014 0.058 0.093 136.33 0.032 
10 0.034 0.051 79.34 0.013 0.187 0.395 130.91 0.027 
11 0.035 0.059 282.09 0.026 0.051 0.076 79.31 0.020 
12 0.020 0.051 308.27 0.009 0.042 0.110 272.34 0.017 
 
Table A.8 Raw data for Mean Arterial Blood Pressure and Heart Rate for Angiotensin 
II treatment group. 
 
 MAP HR 
Rat 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
1 110 145 35 - - - 
2 67 113 46 - - - 
3 107 129 22 460 480 20 
4 109 143 34 441 450 9 
5 82 125 43 388 478 90 
6 116 172 56 325 329 4 
7 116 148 32 335 374 39 
8 113 123 10 288 348 60 
9 - - - - - - 
10 116 169 53 376 454 78 
11 - - - - - - 
12 110 146 36 353 355 2 
 
SSNA-Splanchnic Sympathetic Nerve Activity; RSNA-Renal Sympathetic Nerve 
Activity; MAP-Mean Arterial Pressure; HR-Heart Rate. 
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Table A.9 Raw data for Small Conductance Ca2+ Activated K+ Channel (1-3) Western 
Blot Protein Expression. 
 
Flourescent Intensity Normalized to β-actin 
SK1-
NS 
SK1-AngII-
Salt 
SK2-
NS 
SK2-AngII-
salt 
SK3-
NS 
SK3-AngII-
salt 
0.42 0.48 0.93 0.90 0.66 0.67 
0.39 0.37 0.84 0.88 0.67 0.46 
0.40 0.33 0.89 0.72 0.62 0.47 
0.43 0.48 0.90 0.85 0.59 0.54 
0.38 0.46 0.77 0.81 0.50 0.52 
0.40 0.47 0.76 0.83 0.51 0.56 
0.44 0.50 0.81 0.87 0.50 0.60 
 
SK- Small Conductance Ca2+ Activated K+ Channel; NS-Normal Salt; AngII-salt-
AngiotensinII-Salt Hypertension. 
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Appendix B. Summary Statistics for Study 1. 
 
Table B.1 Mean splanchnic sympathetic nerve activity % change from baseline 
following PVN microinjection of apamin. 
 
  NS AngII-salt HS AngII 
Number of values 8 5 8 5 
Mean 263.50 36.44 125.50 181.60 
Std. Deviation 112.10 35.13 60.80 129.60 
Std. Error 39.65 15.71 21.49 57.94 
          
Lower 95% CI of 
mean 169.80 -7.17 74.65 20.71 
Upper 95% CI of 
mean 357.30 80.06 176.30 342.40 
 
Table B.2 Mean renal sympathetic nerve activity % change from baseline following 
PVN microinjection of apamin. 
 
  NS AngII-salt HS AngII 
Number of values 8 5 8 5 
Mean 179.80 25.32 62.88 75.05 
Std. Deviation 57.87 42.83 45.82 62.15 
Std. Error 19.29 16.19 17.32 27.79 
          
Lower 95% CI of 
mean 135.30 -14.29 20.51 -2.11 
Upper 95% CI of 
mean 224.30 64.93 105.30 152.20 
 
Std.-standard; NS-normal salt; AngII -Angiotensin II; HS-high salt; CI-confidence 
interval. 
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Table B.3 Mean change from baseline for mean arterial pressure (mmHg) following 
PVN microinjection of apamin. 
 
  NS AngII-salt HS AngII 
Number of values 10 7 7 7 
Mean 36.74 11.29 19.86 34.29 
Std. Deviation 13.90 16.33 13.93 5.41 
Std. Error 4.40 6.17 5.27 2.04 
          
Lower 95% CI of 
mean 26.79 -3.81 6.97 29.28 
Upper 95% CI of 
mean 46.68 26.39 32.74 39.29 
 
 
Table B.4 Mean change from baseline for heart rate (beats/minute) following PVN 
microinjection of apamin. 
 
  NS AngII-salt HS AngII 
Number of values 8 9 8 6 
Mean 37.70 4.78 15.13 16.00 
Std. Deviation 34.69 24.43 31.07 13.25 
Std. Error 12.26 8.14 10.99 5.41 
          
Lower 95% CI of 
mean 8.70 -14.00 -10.85 2.09 
Upper 95% CI of 
mean 66.70 23.56 41.10 29.91 
 
Std.-standard; NS-normal salt; AngII -Angiotensin II; HS-high salt; CI-confidence 
interval. 
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Table B.5 One-way ANOVA for splanchnic sympathetic nerve activity % change 
from baseline following PVN microinjection of apamin. 
 
One-way analysis of variance       
P value 0.002   
Number of groups 4   
F 6.855   
R square 0.4831   
    
Bartlett's test for equal variances    
Bartlett's statistic (corrected) 7.359   
P value 0.0613   
    
ANOVA Table SS df MS 
Treatment (between columns) 173841 3 57947 
Residual (within columns) 185977 22 8454 
Total 359818 25  
    
Newman-Keuls 
Mean 
Diff. q P < 0.05? 
AngII-salt vs NS -227.1 6.126 Yes 
AngII-salt vs AngII only -145.1 3.53 No 
AngII-salt vs HS -89.04 --- No 
HS vs NS -138 4.246 Yes 
HS vs AngII -56.09 --- No 
AngII  vs NS -81.94 2.211 No 
 
NS-normal salt; AngII -Angiotensin II; HS-high salt 
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Table B.6 One-way ANOVA for renal sympathetic nerve activity % change from 
baseline following PVN microinjection of apamin. 
 
One-way analysis of variance       
P value < 0.0001   
Number of groups 4   
F 13.1   
R square 0.6208   
    
Bartlett's test for equal variances    
Bartlett's statistic (corrected) 0.984   
P value 0.8051   
    
ANOVA Table SS df MS 
Treatment (between columns) 107810 3 35937 
Residual (within columns) 65840 24 2743 
Total 173649 27  
    
Newman-Keuls 
Mean 
Diff. q P < 0.05? 
AngII-salt vs NS -154.5 8.276 Yes 
AngII-salt vs AngII only -49.73 2.293 No 
AngII-salt vs HS -37.56 --- No 
HS vs NS -116.9 6.264 Yes 
HS vs AngII -12.17 --- No 
AngII vs NS -104.7 5.07 Yes 
 
NS-normal salt; AngII -Angiotensin II; HS-high salt 
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Table B.7 One-way ANOVA for change from baseline for mean arterial pressure 
(mmHg) following PVN microinjection of apamin. 
 
One-way analysis of variance       
P value 0.0018   
Number of groups 4   
F 6.543   
R square 0.4209   
    
Bartlett's test for equal variances    
Bartlett's statistic (corrected) 6.045   
P value 0.1095   
    
ANOVA Table SS df MS 
Treatment (between columns) 3401 3 1134 
Residual (within columns) 4678 27 173.3 
Total 8078 30  
    
Newman-Keuls 
Mean 
Diff. q P < 0.05? 
AngII-salt vs NS -25.45 5.548 Yes 
AngII-salt vs AngII only -23 4.623 Yes 
AngII-salt vs HS -8.571 1.723 No 
HS vs NS -16.88 3.68 Yes 
HS vs AngII -14.43 2.9 No 
AngII vs NS -2.449 0.534 No 
 
NS-normal salt; AngII -Angiotensin II; HS-high salt 
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Table B.8 One-way ANOVA for change from baseline for heart rate (beats/minute) 
following PVN microinjection of apamin. 
 
One-way analysis of variance       
P value 0.1292   
Number of groups 4   
F 2.059   
R square 0.1862   
    
Bartlett's test for equal variances    
Bartlett's statistic (corrected) 4.491   
P value 0.2131   
    
ANOVA Table SS df MS 
Treatment (between columns) 4767 3 1589 
Residual (within columns) 20835 27 771.7 
Total 25602 30  
    
Newman-Keuls 
Mean 
Diff. q P < 0.05? 
AngII-salt vs NS 32.92 3.449 No 
AngII-salt vs AngII only -11.22 - No 
AngII-salt vs HS -10.35 - No 
HS vs NS 22.57 - No 
HS vs AngII -0.875 - No 
AngII vs NS 21.7 - No 
 
NS-normal salt; AngII -Angiotensin II; HS-high salt   
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Appendix C. Raw Data for Study 2. 
 
Table C.1 Raw data for Splanchnic and Renal Sympathetic Nerve Activity for 
Thapsigargin 0.15nmol treatment group. 
 
 SSNA RSNA 
Rat 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
1 0.063 0.068 18.939 0.037 0.046 0.049 10.000 0.016 
2 0.027 0.032 36.913 0.012 0.022 0.024 24.138 0.013 
3 0.050 0.052 5.277 0.012 0.050 0.052 5.743 0.020 
4 0.047 0.049 7.358 0.017 0.068 0.072 7.984 0.018 
 
Table C.2 Raw data for Mean Arterial Blood Pressure and Heart Rate for 
Thapsigargin 0.15nmol  treatment group. 
 
 MAP HR 
Rat 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
1 100 99 -1 348 344 -4 
2 97 101 4 369 386 17 
3 131 128 -3 323 331 8 
4 98 103 5 349 356 7 
 
SSNA-Splanchnic Sympathetic Nerve Activity; RSNA-Renal Sympathetic Nerve 
Activity; MAP-Mean Arterial Pressure; HR-Heart Rate. 
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Table C.3 Raw data for Splanchnic and Renal Sympathetic Nerve Activity for 
Thapsigargin 0.30nmol treatment group. 
 
 SSNA RSNA 
Rat 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
1 0.038 0.041 18.497 0.021 0.025 0.029 27.211 0.011 
2 0.046 0.061 53.546 0.018 0.016 0.018 26.804 0.006 
3 0.023 0.029 45.070 0.009 0.019 0.020 6.604 0.009 
4 0.032 0.036 20.833 0.013 0.011 0.012 20.000 0.007 
5 0.046 0.052 29.891 0.028 0.037 0.041 14.634 0.008 
 
 
Table C.4 Raw data for Mean Arterial Blood Pressure and Heart Rate for 
Thapsigargin 0.30nmol treatment group. 
 
 MAP HR 
Rat 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
1 124 130 6 311 317 6 
2 110 118 8 352 350 -2 
3 109 112 3 353 357 4 
4 95 109 14 333 334 1 
5 136 138 2 340 350 10 
 
 
SSNA-Splanchnic Sympathetic Nerve Activity; RSNA-Renal Sympathetic Nerve 
Activity; MAP-Mean Arterial Pressure; HR-Heart Rate. 
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Table C.5 Raw data for Splanchnic and Renal Sympathetic Nerve Activity for 
Thapsigargin 0.75nmol treatment group. 
 
 SSNA RSNA 
Rat 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
1 0.025 0.036 83.745 0.012 - - - - 
2 0.036 0.054 90.863 0.017 0.021 0.029 86.364 0.012 
3 0.028 0.040 79.021 0.014 0.029 0.038 85.714 0.018 
4 0.044 0.064 91.781 0.022 0.023 0.030 60.345 0.011 
5 0.019 0.030 121.053 0.009 0.016 0.021 57.471 0.007 
6 0.052 0.081 86.747 0.019 0.074 0.109 68.279 0.022 
 
Table C.6 Raw data for Mean Arterial Blood Pressure and Heart Rate for 
Thapsigargin 0.75nmol treatment group. 
 
 MAP HR 
Rat 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
1 108 125 17 346 370 24 
2 123 137 14 337 341 4 
3 113 126 13 330 342 12 
4 82 92 10 362 368 6 
5 110 114 4 373 375 2 
6 105 109 4 354 356 2 
 
SSNA-Splanchnic Sympathetic Nerve Activity; RSNA-Renal Sympathetic Nerve 
Activity; MAP-Mean Arterial Pressure; HR-Heart Rate. 
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Table C.7 Raw data for Splanchnic and Renal Sympathetic Nerve Activity for 
Thapsigargin 1.5nmol treatment group. 
 
 SSNA RSNA 
Rat 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
1 0.031 0.044 82.166 0.015 0.020 0.023 28.125 0.007 
2 0.022 0.030 71.171 0.011 - - - - 
3 0.023 0.031 62.097 0.011 0.032 0.052 112.360 0.014 
4 0.020 0.032 109.009 0.009 0.038 0.050 41.554 0.008 
5 0.019 0.029 84.821 0.008 0.015 0.024 92.553 0.006 
 
Table C.8 Raw data for Mean Arterial Blood Pressure and Heart Rate for 
Thapsigargin 1.5nmol treatment group. 
 
 MAP HR 
Rat 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
1 106 118 12 348 349 1 
2 115 123 8 352 375 23 
3 114 120 6 322 335 13 
4 114 122 8 366 387 21 
5 107 116 9 294 298 4 
 
SSNA-Splanchnic Sympathetic Nerve Activity; RSNA-Renal Sympathetic Nerve 
Activity; MAP-Mean Arterial Pressure; HR-Heart Rate. 
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Table C.9 Raw data for Splanchnic and Renal Sympathetic Nerve Activity for 
Thapsigargin 0.75nmol in High Salt diet treatment group. 
 
 SSNA RSNA 
Rat 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
1 0.032 0.038 32.940 0.011 - - - - 
2 - - - - 0.013 0.016 34.276 0.005 
3 - - - - 0.027 0.031 33.813 0.013 
4 0.068 0.085 52.199 0.034 - - - - 
5 0.073 0.079 23.556 0.051 0.050 0.054 14.098 0.020 
6 0.037 0.043 28.571 0.016 0.009 0.010 44.444 0.006 
7 0.019 0.022 54.717 0.014 0.034 0.037 15.217 0.011 
8 0.047 0.050 10.248 0.015 0.036 0.039 16.372 0.013 
 
 
Table C.10 Raw data for Mean Arterial Blood Pressure and Heart Rate for 
Thapsigargin 0.75nmol in High Salt diet treatment group. 
 
 MAP HR 
Rat 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
1 104 120 16 318 315 -3 
2 99 109 10 328 346 18 
3 114 122 8 368 370 2 
4 113 124 11 312 320 8 
5 80 82 1 248 244 -4 
6 114 127 13 304 306 2 
7 112 117 5 366 380 14 
8 113 110 -3 355 357 2 
 
 
SSNA-Splanchnic Sympathetic Nerve Activity; RSNA-Renal Sympathetic Nerve 
Activity; MAP-Mean Arterial Pressure; HR-Heart Rate. 
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Table C.11 Raw data for Splanchnic and Renal Sympathetic Nerve Activity for 
Thapsigargin 0.75nmol intravenous infusion. 
 
 SSNA RSNA 
Rat 
Base 
(µV) 
Max 
(µV) 
%Chan
ge 
Noise 
(µV) 
Base 
(µV) 
Max 
(µV) 
%Chan
ge 
Noise 
(µV) 
1 - - - - 0.040 0.044 14.232 0.013 
2 0.016 0.017 8.974 0.008 0.025 0.026 4.023 0.008 
3 0.026 0.027 2.837 0.012 0.071 0.072 1.167 0.020 
4 0.026 0.027 6.098 0.010 0.040 0.038 -9.524 0.019 
 
 
Table C.12 Raw data for Mean Arterial Blood Pressure and Heart Rate for 
Thapsigargin 0.75nmol in High Salt diet treatment group. 
 
 MAP HR 
Rat 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
1 120 123 -3 301 306 5 
2 114 94 -20 406 403 -3 
3 123 125 2 346 343 -3 
4 86 87 1 317 322 5 
 
 
SSNA-Splanchnic Sympathetic Nerve Activity; RSNA-Renal Sympathetic Nerve 
Activity; MAP-Mean Arterial Pressure; HR-Heart Rate. 
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Table C.13 Raw data for Splanchnic and Renal Sympathetic Nerve Activity for 
Thapsigargin 0.75nmol microinjection in the lateral hypothalamus. 
 
 SSNA RSNA 
Rat 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
1 - - - - 0.038 0.036 -7.968 0.013 
2 0.023 0.025 15.000 0.013 - - - - 
3 0.018 0.021 31.633 0.008 0.028 0.033 24.631 0.008 
4 0.024 0.024 -1.563 0.012 0.066 0.065 -1.316 0.020 
5 0.029 0.031 -2.985 0.096 0.037 0.037 1.667 0.019 
 
Table C.14 Raw data for Mean Arterial Blood Pressure and Heart Rate for 
Thapsigargin 0.75nmol in microinjection in the lateral hypothalamus. 
 
 MAP HR 
Rat 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
1 116 114 -2 318 305 -13 
2 121 120 -1 291 294 3 
3 114 116 2 405 417 12 
4 117 120 3 339 329 -10 
5 88 89 1 332 323 -9 
 
SSNA-Splanchnic Sympathetic Nerve Activity; RSNA-Renal Sympathetic Nerve 
Activity; MAP-Mean Arterial Pressure; HR-Heart Rate. 
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Table C.15 Raw data for Splanchnic and Renal Sympathetic Nerve Activity for 
DMSO (vehicle) microinjection in paraventricular nucleus. 
 
 
 SSNA RSNA 
Rat 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
Base 
(µV) 
Max 
(µV) %Change 
Noise 
(µV) 
1 0.038 0.039 3.211 0.016 0.023 0.025 9.756 0.011 
2 0.020 0.020 1.695 0.008 0.016 0.015 -10.000 0.006 
3 0.026 0.026 1.325 0.011 0.026 0.027 3.468 0.009 
 
Table C.16 Raw data for Mean Arterial Blood Pressure and Heart Rate for DMSO 
(vehicle) microinjection in paraventricular nucleus. 
 
 MAP HR 
Rat 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
Base 
(mmHg) 
Max 
(mmHg) 
Delta 
(mmHg) 
1 126 125 -1 357 358 1 
2 105 105 0 290 284 -6 
3 103 107 4 410 402 -8 
 
SSNA-Splanchnic Sympathetic Nerve Activity; RSNA-Renal Sympathetic Nerve 
Activity; MAP-Mean Arterial Pressure; HR-Heart Rate. 
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Table C.17 Firing frequency in response to step current injection in PVN-RVLM 
neurons from normal salt rats. 
 NS Control Firing Frequency (Hz) 
Current Injection Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Cell 7 Cell 8 
50 1.25 0.00 0.00 3.75 6.25 0.00 1.25 0.00 
100 6.25 7.50 11.25 13.75 12.50 7.50 5.00 6.25 
150 11.25 12.50 20.00 22.50 16.25 15.00 13.75 13.75 
200 15.00 17.50 28.75 30.00 20.00 21.25 21.25 21.25 
 
 
Table C.18 Firing frequency in response to step current injection in PVN-RVLM 
neurons from normal salt rats following bath application of Thapsigargin. 
 
 NS Thapsigargin Firing Frequency (Hz) 
Current Injection Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 
50 0.00 6.25 6.25 7.50 1.25 10.00 
100 8.75 17.50 16.25 12.50 7.50 33.75 
150 22.50 27.50 31.25 18.75 13.75 27.50 
200 32.50 37.50 41.25 32.50 17.50 7.50 
 
PVN-paraventricular nucleus; RVLM-rostralventrolateral medulla; NS-normal salt; 
Hz-Hertz 
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Table C.19 Firing frequency in response to step current injection in PVN-RVLM 
neurons from high salt rats. 
 
 HS Control Firing Frequency (Hz) 
Current Injection Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 
50 5.00 2.50 8.75 0.00 0.00 
100 25.00 6.25 18.75 7.50 10.00 
150 40.00 16.25 30.00 13.75 18.75 
200 47.50 26.25 37.50 21.25 36.25 
 
Table C.20 Firing frequency in response to step current injection in PVN-RVLM 
neurons from high salt rats following bath application of Thapsigargin. 
 
 HS Thapsigargin Firing Frequency (Hz) 
Current Injection Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 
50 1.25 1.25 5.00 6.25 5.00 7.50 
100 6.25 6.25 11.25 15.00 10.00 28.75 
150 16.25 15.00 17.50 33.75 17.50 42.50 
200 25.00 18.75 23.75 46.25 26.25 52.5 
 
PVN-paraventricular nucleus; RVLM-rostralventrolateral medulla; NS-normal salt; 
Hz-Hertz 
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Table C.21 Resting membrane potential (mV) in PVN-RVLM neurons from normal 
salt and high salt rats. 
 
Cell NS NS TG HS HS TG 
1 -69.00 -50.00 -49.00 -51.00 
2 -60.00 -59.00 -55.00 -65.00 
3 -61.00 -52.00 -48.00 -65.00 
4 -64.00 -59.00 -58.00 -51.00 
5 -51.00 -67.00 -60.00 -57.00 
6 -55.00 -64.00 -44.00 -59.00 
7 -59.00 - -53.00 - 
8 -51.00 - - - 
 
 
Table C.22 Membrane capacitance (pF) in PVN-RVLM neurons from normal salt and 
high salt rats. 
 
Cell NS NS TG HS HS TG 
1 70.00 39.00 45.00 44.00 
2 68.00 33.00 27.00 73.00 
3 44.00 31.00 28.00 61.00 
4 47.00 44.00 59.00 32.00 
5 44.00 61.00 49.00 37.00 
6 48.00 30.00 34.00 38.00 
7 47.00 - 36.00 - 
8 54.00 - - - 
 
pF-picofarads; PVN-paraventricular nucleus; RVLM rostral ventrolateral medulla; NS 
normal salt; HS-high salt; TG-thapsigargin 
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Table C.23 Depolarizing input resistance (GigaOhm) in PVN-RVLM neurons from 
normal salt and high salt rats. 
 
   
Cell NS NS TG HS HS TG 
1 0.67 0.52 0.75 0.66 
2 0.53 0.30 0.78 0.55 
3 0.64 1.10 0.78 0.62 
4 0.59 1.19 0.52 0.90 
5 0.78 0.68 0.50 0.82 
6 0.60 0.86 0.85 0.66 
7 0.64 - 1.12 - 
8 0.49 - - - 
 
 
Table C.24 Sub-threshold of membrane potential to fire action potential (mV) in 
PVN-RVLM neurons from normal salt and high salt rats. 
 
Cell NS NS TG HS HS TG 
1 0.67 0.52 0.75 0.66 
2 0.53 0.30 0.78 0.55 
3 0.64 1.10 0.78 0.62 
4 0.59 1.19 0.52 0.90 
5 0.78 0.68 0.50 0.82 
6 0.60 0.86 0.85 0.66 
7 0.64 - 1.12 - 
8 0.49 - - - 
 
 
mV-millivolts; PVN-paraventricular nucleus; RVLM rostral ventrolateral medulla; NS 
normal salt; HS-high salt; TG-thapsigargin 
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Table C.25 Inter-spike interval (milliseconds) in PVN-RVLM neurons from normal 
salt rats. 
 Inter-Spike Interval (milliseconds) NS 
AP # Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 Cell 7 Cell 8 
1 10.95 35.20 15.80 25.00 21.40 31.60 28.40 24.70 
2 12.74 39.70 20.60 26.50 25.80 46.40 29.40 27.20 
3 13.57 40.80 23.60 26.50 28.30 48.50 35.10 28.90 
4 13.83 48.00 27.20 30.20 34.50 45.70 34.60 28.70 
5 13.19 54.70 32.50 29.60 39.40 51.30 47.00 30.40 
6 13.04 55.50 34.60 28.30 50.60 49.10 44.20 33.90 
7 12.92 61.50 37.90 30.60 44.50 46.00 43.50 38.00 
8 14.43 58.40 34.00 32.70 50.90 49.60 56.30 40.80 
9 12.56 63.40 38.30 31.30 50.40 51.70 49.10 41.50 
10 13.89 67.60 36.30 33.30 53.60 50.70 55.20 50.50 
 
 
Table C.26 Inter-spike interval (milliseconds) in PVN-RVLM neurons from normal 
salt rats following bath application of thapsigargin. 
 Inter-Spike Interval (milliseconds) NS TG 
AP # Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 
1 23.60 29.70 15.30 69.80 13.70 23.50 
2 25.00 26.10 19.40 62.00 14.50 26.00 
3 26.00 30.80 20.70 64.90 15.90 28.50 
4 27.90 25.70 22.70 58.40 16.90 33.00 
5 29.20 23.20 23.00 65.00 18.80 41.50 
6 30.00 23.70 24.50 64.70 20.60 45.50 
7 31.00 23.90 23.70 57.90 22.70 51.50 
8 30.10 24.70 24.80 53.60 24.00 57.00 
9 29.80 21.10 24.50 61.30 25.10 60.00 
10 31.60 25.10 22.10 61.50 25.60 64.00 
 
 
PVN-paraventricular nucleus; RVLM rostral ventrolateral medulla; NS normal salt; 
HS-high salt; TG-thapsigargin; AP Action potential 
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Table C.27 Inter-spike interval (milliseconds) in PVN-RVLM neurons from high salt 
rats following bath application of thapsigargin. 
 
 Inter-Spike Interval (milliseconds) HS 
AP# Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 
1 16.10 16.50 15.20 26.90 10.00 13.20 
2 17.90 19.40 16.60 30.30 13.00 14.00 
3 19.00 21.70 17.40 31.00 15.30 15.80 
4 20.30 21.20 18.60 36.20 17.50 16.30 
5 20.00 23.70 20.20 40.40 15.80 16.20 
6 20.00 30.80 23.60 41.40 16.80 17.40 
7 21.00 31.00 24.80 45.90 22.90 16.90 
8 21.50 30.80 25.20 49.20 23.60 18.10 
9 20.80 35.80 23.40 52.30 20.70 18.50 
10 21.20 38.10 25.50 51.00 26.10 18.40 
 
Table C.28 Inter-spike interval (milliseconds) in PVN-RVLM neurons from high salt 
rats following bath application of thapsigargin. 
 
 Inter-Spike Interval (milliseconds) HS TG 
AP # Cell 1 Cell 2 Cell 3 Cell 4 Cell 5 Cell 6 
1 27.00 28.50 36.50 12.70 15.20 18.60 
2 29.60 33.50 37.30 14.40 15.50 18.90 
3 33.10 37.10 37.30 16.00 16.20 24.60 
4 34.30 39.60 33.60 16.10 16.00 17.90 
5 34.50 45.60 34.40 16.70 16.70 20.00 
6 37.20 48.60 36.90 17.70 18.00 18.20 
7 37.60 58.50 37.30 20.50 18.50 17.80 
8 42.20 63.00 35.70 20.60 20.10 17.80 
9 42.90 66.70 36.90 19.40 21.10 17.80 
10 49.80 64.00 37.50 21.50 21.10 16.50 
 
PVN-paraventricular nucleus; RVLM rostral ventrolateral medulla; NS normal salt; 
HS-high salt; TG-thapsigargin; AP Action potential 
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Appendix D. Summary Statistics for Study 2. 
 
Table D.1 Mean splanchnic sympathetic nerve activity % change from baseline 
following PVN microinjection of Thapsigargin in normal rats. 
 
  DMSO TG 0.15nmol TG 0.30nmol TG 0.75nmol TG 1.5nmol 
Number of values 3 4 5 6 5.00 
Mean 2.07 17.13 33.56 92.22 81.84 
Std. Deviation 1.00 14.48 15.29 14.92 17.67 
Std. Error 0.58 7.24 6.84 6.09 7.90 
            
Lower 95% CI of mean -0.42 -5.91 14.57 76.56 59.90 
Upper 95% CI of mean 4.56 40.16 52.55 107.90 103.80 
 
Table D.2 Mean renal sympathetic nerve activity % change from baseline following 
PVN microinjection of Thapsigargin in normal rats. 
 
  DMSO TG 0.15nmol TG 0.30nmol TG 0.75nmol TG 1.5nmol 
Number of values 3 4 5 5 4.00 
Mean 1.10 11.95 19.06 71.62 68.67 
Std. Deviation 10.12 8.29 8.68 13.75 40.27 
Std. Error 5.84 4.14 3.88 6.15 20.13 
            
Lower 95% CI of mean -24.03 -1.24 8.28 54.55 4.60 
Upper 95% CI of mean 26.23 25.14 29.84 88.69 132.70 
 
DMSO-dimethyl sulfoxide; TG-thapsigargin; Std-standard; CI-confidence interval 
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Table D.3 Average mean arterial blood pressure change from baseline following PVN 
microinjection of Thapsigargin in normal rats. 
 
  DMSO TG 0.15nmol TG 0.30nmol TG 0.75nmol TG 1.5nmol 
Number of values 3 4 5 6 5.00 
Mean 1.00 1.25 6.60 10.33 8.60 
Std. Deviation 2.65 3.86 4.78 5.39 2.19 
Std. Error 1.53 1.93 2.14 2.20 0.98 
            
Lower 95% CI of mean -5.57 -4.90 0.67 4.68 5.88 
Upper 95% CI of mean 7.57 7.40 12.53 15.99 11.32 
 
 
Table D.4 Average heart rate (beats/minute) change from baseline following PVN 
microinjection of Thapsigargin in normal rats. 
 
  DMSO TG 0.15nmol TG 0.30nmol TG 0.75nmol TG 1.5nmol 
Number of values 3 4 5 6 5.00 
Mean -4.33 7.00 3.80 8.33 12.40 
Std. Deviation 4.73 8.60 4.60 8.52 9.84 
Std. Error 2.73 4.30 2.06 3.48 4.40 
            
Lower 95% CI of mean -16.07 -6.69 -1.92 -0.61 0.18 
Upper 95% CI of mean 7.41 20.69 9.52 17.28 24.62 
 
DMSO-dimethyl sulfoxide; TG-thapsigargin; Std-standard; CI-confidence interval 
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Table D.5 Mean splanchnic sympathetic nerve activity % change from baseline 
following PVN microinjection of Thapsigargin in normal control and high salt rats. 
 
  HS TG TG IV TG Lat Hypo 
Number of values 6 3 4 
Mean 33.71 5.97 10.52 
Std. Deviation 17.11 3.07 16.27 
Std. Error of Mean 6.99 1.77 8.14 
        
Lower 95% CI of 
mean 15.75 -1.66 -15.37 
Upper 95% CI of 
mean 51.66 13.60 36.41 
 
Table D.6 Mean renal sympathetic nerve activity % change from baseline following 
PVN microinjection of Thapsigargin in normal control and high salt rats. 
 
  HS TG TG IV TG Lat Hypo 
Number of values 6 4 4 
Mean 26.37 2.48 4.25 
Std. Deviation 12.80 9.77 14.17 
Std. Error of Mean 5.23 4.89 7.09 
        
Lower 95% CI of 
mean 12.93 -13.07 -18.29 
Upper 95% CI of 
mean 39.81 18.02 26.80 
 
TG-thapsigargin; Std-standard; CI-confidence interval; HS-high salt; IV-intravenous; 
Lat Hypo-Lateral Hypothalamus 
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Table D.7 Average mean arterial blood pressure change from baseline following PVN 
microinjection of Thapsigargin in normal control and high salt rats. 
 
  HS TG TG IV TG Lat Hypo 
Number of values 8 4 5 
Mean 7.63 -5.00 0.60 
Std. Deviation 6.32 10.23 2.07 
Std. Error of Mean 2.24 5.12 0.93 
        
Lower 95% CI of 
mean 2.34 -21.28 -1.98 
Upper 95% CI of 
mean 12.91 11.28 3.18 
 
Table D.8 Average heart rate (beats/minute) change from baseline following PVN 
microinjection of Thapsigargin in normal rats. 
 
  HS TG TG IV TG Lat Hypo 
Number of values 8 4 5 
Mean 4.88 1.00 -3.40 
Std. Deviation 7.85 4.62 10.55 
Std. Error of Mean 2.77 2.31 4.72 
        
Lower 95% CI of 
mean -1.68 -6.35 -16.50 
Upper 95% CI of 
mean 11.43 8.35 9.70 
 
TG-thapsigargin; Std-standard; CI-confidence interval; HS-high salt; IV-intravenous; 
Lat Hypo-Lateral Hypothalamus 
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Table D.9 One-way ANOVA for splanchnic sympathetic nerve activity % change 
from baseline following microinjection of thapsigargin in the PVN. 
 
ANOVA summary      
F 32.3     
P value <0.0001     
R square 0.8777     
      
Brown-Forsythe test      
F (DFn, DFd) 
0.7917 (4, 
18)     
P value 0.5457     
      
ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between 
columns) 28198 4 7050 
F (4, 18) = 
32.3 
P<0.000
1 
Residual (within columns) 3928 18 218.2   
Total 32126 22    
      
Newman-Keuls Mean Diff. 
Significant
? 
Summar
y   
DMSO vs. TG 0.15nmol -15.06 No ns   
DMSO vs. TG 0.30nmol -31.49 Yes *   
DMSO vs. TG 0.75nmol -90.15 Yes ****   
DMSO vs. TG 1.5nmol -79.77 Yes ****   
TG 0.15nmol vs. TG 
0.30nmol -16.44 No ns   
TG 0.15nmol vs. TG 
0.75nmol -75.09 Yes ****   
TG 0.15nmol vs. TG 
1.5nmol -64.72 Yes ****   
TG 0.30nmol vs. TG 
0.75nmol -58.66 Yes ****   
TG 0.30nmol vs. TG 
1.5nmol -48.28 Yes ****   
TG 0.75nmol vs. TG 
1.5nmol 10.38 No ns   
 
 
DMSO-dimethylsulfoxide; TG-thapsigargin 
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Table D.10 One-way ANOVA for renal sympathetic nerve activity % change from 
baseline following microinjection of thapsigargin in the PVN. 
 
ANOVA summary      
F 11.36     
P value 0.0001     
R square 0.7397     
      
Brown-Forsythe test      
F (DFn, DFd) 
11.1 (4, 
16)     
P value 0.0002     
      
ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between 
columns) 17990 4 4498 
F (4, 16) = 
11.36 P<0.001 
Residual (within columns) 6332 16 395.7   
Total 24322 20    
      
Newman-Keuls 
Mean 
Diff. 
Significant
? 
Summa
ry   
DMSO vs. TG 0.15nmol -10.85 No ns   
DMSO vs. TG 0.30nmol -17.96 No ns   
DMSO vs. TG 0.75nmol -70.52 Yes **   
DMSO vs. TG 1.5nmol -67.57 Yes **   
TG 0.15nmol vs. TG 
0.30nmol -7.11 No ns   
TG 0.15nmol vs. TG 
0.75nmol -59.67 Yes **   
TG 0.15nmol vs. TG 
1.5nmol -56.72 Yes **   
TG 0.30nmol vs. TG 
0.75nmol -52.56 Yes **   
TG 0.30nmol vs. TG 
1.5nmol -49.61 Yes **   
TG 0.75nmol vs. TG 
1.5nmol 2.95 No ns   
 
 
DMSO-dimethylsulfoxide; TG-thapsigargin 
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Table D.11 One-way ANOVA for mean arterial blood pressure (mmHg) change from 
baseline following microinjection of thapsigargin in the PVN. 
 
ANOVA summary      
F 4.446     
P value 0.0113     
R square 0.497     
      
Brown-Forsythe test      
F (DFn, DFd) 
1.36 (4, 
18)     
P value 0.2869     
      
ANOVA table SS DF MS F (DFn, DFd) 
P 
value 
Treatment (between 
columns) 310.7 4 77.68 
F (4, 18) = 
4.446 P=0.01 
Residual (within columns) 314.5 18 17.47   
Total 625.2 22    
      
Newman-Keuls 
Mean 
Diff. 
Significant
? 
Summar
y   
DMSO vs. TG 0.15nmol -0.25 No ns   
DMSO vs. TG 0.3nmol -5.6 No ns   
DMSO vs. TG 0.75nmol -9.333 Yes *   
DMSO vs. TG 1.5nmol -7.6 No ns   
TG 0.15nmol vs. TG 
0.3nmol -5.35 No ns   
TG 0.15nmol vs. TG 
0.75nmol -9.083 Yes *   
TG 0.15nmol vs. TG 
1.5nmol -7.35 No ns   
TG 0.3nmol vs. TG 
0.75nmol -3.733 No ns   
TG 0.3nmol vs. TG 1.5nmol -2 No ns   
TG 0.75nmol vs. TG 
1.5nmol 1.733 No ns   
 
 
DMSO-dimethylsulfoxide; TG-thapsigargin 
 
 
 
 
128 
 
Table D.12 One-way ANOVA for heart rate (beats/minute) change from baseline 
following microinjection of thapsigargin in the PVN. 
 
ANOVA summary      
F 2.382     
P value 0.09     
R square 0.3461     
      
Brown-Forsythe test      
F (DFn, DFd) 
0.6232 (4, 
18)     
P value 0.6519     
      
ANOVA table SS DF MS F (DFn, DFd) 
P 
value 
Treatment (between 
columns) 583.2 4 145.8 
F (4, 18) = 
2.382 P=0.09 
Residual (within columns) 1102 18 61.22   
Total 1685 22    
      
Newman-Keuls Mean Diff. 
Significant
? 
Summar
y   
DMSO vs. TG 0.15nmol -11.33 No ns   
DMSO vs. TG 0.3nmol -8.133 No ns   
DMSO vs. TG 0.75nmol -12.67 No ns   
DMSO vs. TG 1.5nmol -16.73 No ns   
TG 0.15nmol vs. TG 
0.3nmol 3.2 No ns   
TG 0.15nmol vs. TG 
0.75nmol -1.333 No ns   
TG 0.15nmol vs. TG 
1.5nmol -5.4 No ns   
TG 0.3nmol vs. TG 
0.75nmol -4.533 No ns   
TG 0.3nmol vs. TG 1.5nmol -8.6 No ns   
TG 0.75nmol vs. TG 
1.5nmol -4.067 No ns   
 
DMSO-dimethylsulfoxide; TG-thapsigargin 
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Table D.13  Unpaired t-test for slope of the current injection response in normal and 
high salt rats before and after bath application of thapsigargin. 
  Slope Slope Slope 
Column A NS HS NS 
vs. vs vs vs 
Column B NS TG HS TG HS 
        
Unpaired t test       
P value 0.0013 0.8079 0.0017 
P value summary ** ns ** 
One- or two-tailed P 
value? Two-tailed Two-tailed Two-tailed 
t, df t=4.28 df=11 
t=0.2504 
df=9 t=4.399 df=9 
 
 
 
Table D.14  Unpaired t-test for excitability in response to 200pA current injection in 
normal and high salt rats before and after bath application of thapsigargin. 
 
  Excitability Excitability Excitability 
Column A NS HS NS 
vs. vs vs vs 
Column B NS TG HS TG HS 
        
Unpaired t test       
P value 0.0329 0.4399 0.0026 
P value summary ** ns ** 
One- or two-tailed P 
value? One-tailed Two-tailed Two-tailed 
t, df 
t=2.025 
df=12 
t=0.8013 
df=11 
t=3.713 
df=13 
 
 
 
NS-normal salt; TG-thapsigargin; HS-high salt 
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Table D.15  Unpaired t-test for slope of inter-spike interval in normal and high salt 
rats before and after bath application of thapsigargin. 
  Slope Slope Slope 
Column A NS HS NS 
vs. vs. vs vs 
Column B NS TG HS TG HS 
        
Unpaired t test       
P value <0.0001 0.0842 0.0473 
P value summary ** ns * 
One- or two-tailed P 
value? Two-tailed Two-tailed Two-tailed 
t, df 
t=6.111 
df=12 
t=1.917 
df=10 
t=2.261 
df=10 
 
 
NS-normal salt; TG-thapsigargin; HS-high salt 
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Appendix E. Chemical Structures 
Figure E.1 Representative Chemical Structure of the SK Channel Blocker Apamin 
Formula: C79H131N31O24S4
Molecular Weight: 2027.339 g/mol 
132 
Figure E.2 Representative Chemical Structure of the ER Ca2+ ATPase Thapsigargin. 
Formula: C34H50O12
Molecular Weight: 650.79 g/mol 
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Appendix F. Permissions  
Requests for Permission to Reproduce Previously Published Material. 
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Permission for Figure 1.4 
 
 
 
 
Permission for Figure 1.7 
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Permission for Chapter 2. 
 
 
